

## CURRICULUM VITAE

**Date of Revision**      October 21, 2021

**Name**                      Pamela L. Kunz, M.D.  
Associate Professor, Department of Internal Medicine  
Section of Medical Oncology, Clinician Educator Track

**Term**                        July 20, 2020 - June 30, 2025

**School**                      Yale University School of Medicine

### Education

B.A.                          Dartmouth College (Biology) 1994  
M.D.                         Dartmouth Geisel School of Medicine 2001

### Career/Academic Appointments:

2001-04      Intern and Resident in Internal Medicine, Stanford University  
2004-05      Chief Resident in Internal Medicine, Stanford University  
2006-08      Clinical and Research Fellow in Medical Oncology, Stanford University  
2008-09      Instructor of Medicine (Oncology), Stanford University  
2009-10      Acting Assistant Professor of Medicine (Oncology), Stanford University  
2010-20      Assistant Professor of Medicine (Oncology), Stanford University  
2020           Associate Professor of Medicine (Oncology), Stanford University  
2020           Associate Professor of Medicine (Oncology), Yale University

### Board Certification:

American Board of Internal Medicine, Internal Medicine, 2004-2014  
American Board of Internal Medicine, Medical Oncology, 2010-present

### Professional Honors and Recognition

#### International/National/Regional

2021: Woman Oncologist of the Year, Women Leaders of Oncology  
2021: Nominated for Women Who Conquer Cancer Award, ASCO  
2020: Featured alumna of Stanford Internal Medicine Residency for National Women Physicians Day  
2019: Nominated for APP Champion Award for Stanford Hospitals and Clinics  
2018: Nominated for APP Champion Award for Stanford Hospitals and Clinics  
2018: Malinda Mitchell Award for Quality and Service for team project entitled "GI Project-Care Coordination for New Patients, GI Oncology Cancer Center Palo Alto." Awarded while GI Oncology Clinical Research Group Leader.  
2015: Saul Rosenberg Division of Oncology Faculty Teaching Award

- 2008: Recipient of Henzl-Gabor Travel Award for participation in the 2008 Gastrointestinal Cancers Symposium.
- 2001: Merck Manual Award. Given annually to the graduating medical student who best demonstrates academic achievement, outstanding leadership, and commitment to community service; Dartmouth Medical School.
- 2000: Best oral presentation by a medical student or resident. Joint Annual Meeting of the American College of Obstetricians and Gynecologists and the Council on Residency Education in Obstetrics and Gynecology, LA.

**Grant/Clinical Trials History:**

**Current Grants**

Agency: National Institutes of Health

ID#: 1R03CA219722-01A1

Title: Systematic study of variations in imaging techniques and response criteria for well differentiated pancreatic neuroendocrine tumors.

PI: Namrata Vijavergia, MD

Role on Project: Collaborator

Percent Effort: 0%

Direct costs per year: \$92,150

Direct costs for project period: \$184,300

Project Period: 1/1/2020-12/31/2021

**Current Clinical Trials**

Agency: Advanced Accelerator Applications

ID#: NCT03972488

Title: A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients with Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)

Role: Yale site PI, International Steering Committee Member

Percent Effort: 3%

Total costs for project period: NA

Project Period: 10/1/2021-present

**Past Grants:**

Agency: Stanford University (Clayman Gender Research Institute Faculty Fellow)

Title: Gender of principal investigators in phase II and III GI Oncology clinical trials

PI: Pamela Kunz, MD

Percent Effort: 1%

Direct costs per year: \$7500

Direct costs for project period: \$7500

Project Period: 9/2019-8/2020

Agency: Stanford Cancer Center Clinical Innovation Fund

Title: Leveraging a Novel Mouse Model of the Hereditary Pheochromocytoma and Paraganglioma Syndrome: Mechanistic Insights, Prophylactic Possibilities and a New Diagnostic Test

PI: Justin Annes, MD PhD

Role on Project: Co-PI

Percent Effort: 0%

Total costs for project period: \$100,000

Project Period: 1/2018-12/2018

Agency: Stanford Cancer Center Clinical Innovation Fund

Title: Innovation in Nutrition Education: Culinary Kits and Online Courses for Neuroendocrine Tumor Patients

PI: Ray Palko, RD

Role on Project: Co-PI, Physician Supervisor

Percent Effort: 3%

Total costs for project period: \$95,000

Project Period: 1/2018-12/2018

Agency: Emerson Collective Cancer Research Fund

Title: Targeting PKA Signaling in Neuroendocrine Tumors

PI: Julien Sage, PhD

Role on Project: Co-PI

Percent Effort: 0%

Total costs for project period: \$200,000

Project Period: 4/2017-3/2019

Agency: Stanford Cancer Center Clinical Innovation Fund

Title: RECIST for the real world: Using mintLesion™ for routine response assessment for patients with Neuroendocrine Tumors

PI: Pamela Kunz MD

Percent Effort: 10%

Total costs for project period: \$105,888

Project Period: 4/2016-12/2019

Agency: Stanford Cancer Institute

Title: Developmental Cancer Research Award: "A Tissue Microarray for Neuroendocrine Tumors"

PI: Pamela L. Kunz, MD

Percent Effort: 5%

Total costs for project period: \$50,000  
Project Period: 9/1/13-12/31/14

Agency: Caring for Carcinoid Foundation  
Title: Caring for Carcinoid Foundation Neuroendocrine Tumor Biospecimen Consortium  
PI: Pamela L. Kunz, MD  
Percent Effort: 10%  
Total costs for project period: \$160,000  
Project Period: 8/2/09-2/1/13

Agency: NET Research Foundation  
Title: NET-Smart Therapy: A Targeted Prodrug Strategy  
PI: Justin Annes, MD PhD  
Role on Project: Collaborator  
Percent Effort: 0%  
Direct costs per year: \$100,000  
Direct costs for project period: \$100,000  
Project Period: 4/2019-3/2020

### **Past Clinical Trials**

Agency: National Institutes of Health / National Cancer Institute (NCTN Group: ALLIANCE)  
ID#: NCT03375320  
Title: Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)  
Role: Stanford site PI (with plans to open at Yale)  
Percent Effort: 1%  
Total costs for project period (cost per patient): NA  
Project Period: 7/1/19- 12/31/20

Agency: Brahms AG (a subsidiary of ThermoFisher Scientific)  
ID#: NCT03817866  
Title: Chromogranin A as Surveillance Biomarker in Patients With cARcinoids (The CASPAR Study)  
Role: Stanford site PI  
Percent Effort: 1%  
Total costs for project period (cost per patient): NA  
Project Period: 9/8/18-9/20/20

Agency: Xencor  
ID#: NCT03411915

Title: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects with Advanced Neuroendocrine and Gastrointestinal Stromal Tumors

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period (cost per patient): NA

Project Period: 4/3/2018-4/2/20

Agency: Advanced Accelerator Applications

ID#: NCT02705313

Title: Expanded Access Protocol for Therapeutic Use of <sup>177</sup>Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, somatostatin receptor positive neuroendocrine tumours progressive under somatostatin analogue therapy

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 8/2/16-7/31/19

Agency: National Institutes of Health / National Cancer Institute (NCTN Group: ECOG-ACRIN)

ID#: NCT02595424

Title: Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas (EA2142)

Role: Stanford site PI (with plans to open at Yale)

Percent Effort: 1%

Total costs for project period (cost per patient): NA

Project Period: 2/22/16-12/31/20

Agency: Esanex Pharmaceuticals

ID#: NCT02063958

Title: A Phase 1, Open-label, Dose-escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 5/1/15-4/30/17

Agency: Oxigene

Title: A Phase 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Gastrointestinal Neuroendocrine Tumors/Carcinoid (GI-NET) with Elevated Biomarkers.

ID#: NCT02132468

Role: Stanford site PI

Percent Effort: 1%  
Total costs for project period: NA  
Project Period: 10/20/14-9/30/16

Agency: Ipsen  
ID#: NCT02683941  
Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumor Control in Subjects with Well-differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors (A-US-52030-328)  
Role: Stanford site PI  
Percent Effort: 1%  
Total costs for project period: NA  
Project Period: 9/4/14-9/30/17 (closed early due to low accrual)

Agency: Lexicon Pharmaceuticals  
ID#: NCT02026063  
Title: A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606.302)  
Role: Stanford site PI  
Percent Effort: 1%  
Total costs for project period: NA  
Project Period: 9/4/14-9/30/17

Agency: National Institutes of Health / National Cancer Institute (NCTN Group: ECOG-ACRIN)  
ID#: NCT01841736  
Title: A021202, Prospective Randomized Phase II Trial of Pazopanib Versus Placebo in Patients with Progressive Carcinoid Tumors  
Role: Stanford site PI  
Percent Effort: 1%  
Total costs for project period: NA  
Project Period: 6/9/14-12/31/20

Agency: National Institutes of Health / National Cancer Institute (NCTN Group: ECOG)  
ID#: NCT02031536  
Title: E2212, A Randomized, Double-Blinded, Placebo-controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver  
Role: National Co-PI  
Percent Effort: 1%  
Total costs for project period: NA

Project Period: 4/2014-4/2017

Agency: National Institutes of Health / National Cancer Institute (NCTN Group: CALGB)

ID#: NCT01229943

Title: CALGB80701 Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients with Locally Advanced Or Metastatic Pancreatic Neuroendocrine Tumors

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 3/2014-2/2019

Agency: Lexicon Pharmaceuticals

ID#: NCT02063659

Title: A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate in Patients with Carcinoid Syndrome (LX1606.303, non-diarrhea predominant)

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 2/28/14-3/31/16

Agency: National Institutes of Health / National Cancer Institute (NCTN Group: ECOG-ACRIN)

ID#: NCT01824875

Title: E2211, A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors

Role: National PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 5/23/13-12/31/20

Agency: Merrimack Pharmaceuticals

ID#: NCT01774851

Title: Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 3/2013-4/2016

Agency: Lexicon Pharmaceuticals

ID#: NCT01677910

Title: A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog Therapy (LX1606.301, diarrhea predominant)

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 3/1/13-2/29/16

Agency: Advanced Accelerator Applications

ID#: NCT01578239

Title: A multicentre, stratified, open, randomized, comparator-controlled, parallel group phase III study comparing treatment with <sup>177</sup>Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 11/6/12-5/31/20

Agency: Novartis (Investigator Initiated, Multisite)

ID#: NCT01253161

Title: Phase II Study of Pasireotide LAR in Patients with Metastatic Neuroendocrine Carcinomas

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 11/2011-9/2013

Agency: Genentech and Merck (Investigator Initiated)

ID#: NCT01525082

Title: A Phase II Study of Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 9/20/11-10/15/20

Agency: National Institutes of Health / National Cancer Institute (NCTN Group: SWOG)

ID#: NCT00569127

Title: S0518, Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha



Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 9/2010-1/2015

Agency: Genentech (Investigator Initiated)

ID#: NCT00947167

Title: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Role: PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 3/2009-3/2011

Agency: Bristol-Myers Squibb

ID#: NCT00632424

Title: A Phase I Study of Ixabepilone Administered as 3 Oral Doses Each Separated by 6 Hours Every 21 Days in Subjects with Advanced Cancer

Role: Stanford site Co-PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 6/2008-1/2010

Agency: Genentech (Investigator Initiated)

ID#: NCT00780494

Title: A Phase II Study of Capecitabine, Carboplatin, and Bevacizumab for Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 12/2008- 12/2013

Agency: Genentech (Investigator-initiated)

ID#: NCT00661154

Title: Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project

Role: Stanford site Co-Investigator

Percent Effort: 1%

Total costs for project period: NA

Project Period: 2/2008-7/2010

Agency: GlaxoSmithKline

ID#: NCT00725712

Title: A Phase II Study of 2 dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer

Role: Stanford site Co-PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 8/2007-2/2009

Agency: Genentech and Sanofi-Aventis (Investigator-initiated)

ID#: NCT00398320

Title: A phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab for Metastatic or Unresectable Neuroendocrine Tumors

Role: Stanford site PI

Percent Effort: 1%

Total costs for project period: NA

Project Period: 11/2006-11/2009

### **Pending Clinical Trials**

None

### **Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:**

#### **International/National**

2021: "NET Research: What's on the Horizon?" LA Carcinoid Neuroendocrine Tumor Society (LACNETS); virtual.

2021: "Dismantling Gender Disparities in the Global Oncology Workforce Together," chair and speaker, ASCO Annual Meeting; virtual.

2021: "Looking under the Surface: Exposing the Iceberg of sexual harassment," oral abstract discussant. ASCO Annual Meeting; virtual.

2021: "Optimal Second-Line Therapy in Pancreatic NET: PRRT," Great Debates: Gastrointestinal Malignancies, done via Zoom.

2021: "Finding my voice and becoming an advocate for gender equity in medicine," North American Neuroendocrine Tumor Society Women in NETs inaugural keynote address, virtual.

2021: "Sex differences in patients with neuroendocrine neoplasms," European Neuroendocrine Tumor Society Annual Meeting; virtual.

2021: "TKI Therapy," in 'Neuroendocrine Tumors Current State of Care' Education Session, ASCO Gastrointestinal Cancers Symposium, virtual.

2020: "My journey in medicine", Kings Academy High School (CA) conference, done via Zoom.

2020: "Women in STEM", Stanford Online High School (CA) conference, done via Zoom.

2020: "Optimal Second-Line Therapy in Pancreatic NET: Capecitabine and Temozolomide," Great Debates: Gastrointestinal Malignancies, done via Zoom.

- 2020: “Fertility and Family Planning Panel,” Stanford School of Medicine, done via Zoom.
- 2020: “Pathogenesis and Clinical Outcome of Neuroendocrine Tumors”, Plenary talk at the Pituitary Adenoma Nomenclature Workshop (PANOMEN), done via pre-recorded talk.
- 2020: “The ABCs of NETs: Types, treatments, and trials.” Bay Area NET Patient Education Conference, Stanford, CA *\*cancelled due to COVID19\**
- 2020: “Gastroenteropancreatic NET Breakout.” Bay Area NET Tumor Patient Education Conference, Stanford, CA *\*cancelled due to COVID19\**
- 2019: “Management of Pancreatic NETs,” NANETS Regional CME Conference, San Francisco, CA
- 2019: “Oncology” Menlo-Atherton High School Pre-Med Club noon conference series, Atherton, CA
- 2019: “What about immunotherapy?” University of Chicago~NET Research Foundation Neuroendocrine Tumor Patient Education Conference, Chicago, IL
- 2019: “Clinical Trials: What are They and Who Should Enroll?” University of Chicago~NET Research Foundation Neuroendocrine Tumor Patient Education Conference, Chicago, IL
- 2019: “Pancreas NET Breakout.” Bay Area NET Patient Education Conference, San Francisco, CA
- 2019: “Recent Advances and Ongoing Clinical Trials.” Bay Area NET Patient Education Conference, San Francisco, CA
- 2019: “Gender disparities in medicine: Contributing to objective data and finding solutions,” Clayman Institute Faculty Fellows Seminar, Stanford, CA
- 2019: “Neuroendocrine Tumor Survivorship: A model for chronic cancers,” Stanford Cancer Survivorship Lecture Series, Stanford, CA
- 2019: “Case presentation: Selection of Therapy for Well-differentiated, G3 Neuroendocrine Pancreatic NET.” Case mentor and moderator, International Society for GI Oncology, Arlington VA
- 2019: “Key Translational Questions in Neuroendocrine Tumors,” CCSG GI Program Seminar Series, MD Anderson Cancer Center, Houston, TX
- 2019: “Why NETs matter: Diagnosis and Management of Neuroendocrine Tumors,” Bio-Onco Local Summit, Manila, Philippines
- 2018: “Integrating science to improve patient outcomes: Management of neuroendocrine tumors,” Association of Hematology and Medical Oncology of Puerto Rico (AHOMPR) Annual Meeting, Rio Grande, Puerto Rico
- 2018: “Theranostics: The tale of a rare tumor, a receptor and the FDA,” Stanford Medicine Grand Rounds, Stanford, CA
- 2018: “A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211)”. Chicago, IL, ASCO Annual Meeting; Selected for oral presentation in GI Abstract session.
- 2018: “Clinical Trials.” UCLA/Cedars Sinai/City of Hope/NET Research Foundation Neuroendocrine Tumor Patient Education Conference, Stanford, CA
- 2018: “GI NET (Carcinoid) Breakout.” Bay Area NET Patient Education Conference, San Francisco, CA
- 2018: “Recent Advances and Clinical Trials.” Bay Area NET Patient Education Conference, San Francisco, CA
- 2017: “NETs 101: Nomenclature, pathology and epidemiology,” Stanford CME (Course Director: Kunz); Stanford, CA
- 2017: “Current and Future Directions in the Treatment of Pulmonary Neuroendocrine Tumors,” Rush University Hematology/Oncology Grand Rounds (Axis Medical Education CME); Chicago, IL
- 2017: “Carcinoid Syndrome and Management.” Bay Area NET Patient Education Conference, Stanford, CA
- 2017: “NET Primer.” Bay Area NET Patient Education Conference, Stanford, CA

- 2017: “Whole-genome landscape of pancreatic NETs,” ECOG-ACRIN GI Committee Meeting,
- 2017: “Neuroendocrine Tumors: Where Endocrinology and Medical Oncology Intersect,” Stanford Endocrine Grand Rounds; Stanford, CA
- 2016: “The Stanford Neuroendocrine Tumor Program,” 9<sup>th</sup> Comprehensive Cancer Research Training Program; Stanford, CA
- 2016: “NET Worth: Adding Value with the Stanford Neuroendocrine Tumor Program,” Stanford Medicine Grand Rounds; Stanford, CA
- 2016: “Neuroendocrine Tumors,” Endocrine Fellows Teaching Conference; Stanford, CA
- 2016: “Gastrointestinal Cancer Clinical Trials” as part of Stanford Cancer Center Clinical Trials Awareness Week; Stanford, CA
- 2016: “Stanford Trials and NET Program Development”, INKEP Scientific Tour 2016, Stanford, CA
- 2016: “Building a Neuroendocrine Tumor Program” presented to Mariann Byerwalter Acting SHC CEO; Stanford, CA
- 2016: “What Dietitians Need to Know About Neuroendocrine Tumors,” Presentation to Stanford Cancer Center Registered Dietitians; Stanford, CA
- 2016: “Clinical Science Symposium #1: Abstract Discussion,” NANETS Annual Meeting, Jackson, WY
- 2016: “Gastroenteropancreatic Neuroendocrine Tumors,” Saint Agnes – Stanford Hepatobiliary / GI Symposium; Fresno, CA
- 2016: “Imaging and Treatment Algorithms for NETs: A Clinician’s Perspective.” Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting; San Diego, CA
- 2016: “Recent Advances in the Treatment of Neuroendocrine Tumors.” ASCO Gastrointestinal Cancers Symposium, San Francisco, CA
- 2016: “Colorectal Cancer: Screening and Treatment.” Palo Alto High School, Next Generation for Cancer Club, Palo Alto, CA
- 2016: “2015: Year in Review, Results of Recent Trials.” Bay Area NET Patient Education Conference, San Francisco, CA
- 2015: “An Immunotherapy Clinical Trial for NETs.” Bay Area NET Patient Education Conference, Stanford, CA
- 2015: “Essential Concepts in the Use of Somatostatin Analogues in Patients with NETs.” Medscape CME Video
- 2015: “What Does the Current Management Roadmap Look Like for GEP-NETs?” San Francisco, CA; CMEducation Resources
- 2015: “The Oncologist's Perspective on NETs.” Western Region – Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, Monterey, CA
- 2015: “Angiogenesis Inhibitors and Predictive Biomarkers in pNETs.” NANETS Annual Meeting, Austin TX
- 2015: “Building an Independent Clinical Research Program: Mentees, Mentors, and Developing Independence.” NANETS Annual Meeting, Austin TX
- 2015: “Neuroendocrine Tumors: Medical Treatment and Beyond.” ASCO Gastrointestinal Cancers Symposium, San Francisco, CA
- 2015: “Advances in Neuroendocrine Tumors.” Stanford Cancer Center Education Seminar Series, Stanford, CA
- 2014: “GI Tumor Therapies and Disease Course.” Stanford Hospice and Palliative Medicine Fellows Core Seminar Series, Stanford, CA
- 2014: “From Fellow to Faculty: Building an Independent Clinical Research Program.” Stanford Oncology-Hematology Annual Research Retreat, Pacific Grove, CA

- 2014: "Metastatic Gastric Cancer: One Disease or Many." Stanford Cancer Center Education Seminar Series, Stanford, CA
- 2014: "Current Treatment and Clinical Trial Landscape in Pancreatic NETs." NANETS Annual Meeting, Charleston, SC
- 2014: "Emerging Therapeutics." ASCO Annual Meeting Education Session, Chicago, IL
- 2014: "NETs: Who gets them, how to make the diagnosis, and how to treat." Caring for Carcinoid Foundation Neuroendocrine Tumor Patient Education Conference, LA, CA
- 2014: "Current and Future Treatment of HER2-Positive Gastric Cancer." Presented at the CME Course entitled "What Oncology Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Gastrointestinal Cancers." San Francisco, CA
- 2013: "Clinical Trials 101." Bay Area NET Patient Education Conference, Stanford, CA
- 2013: "Consensus Guidelines Updates." NANETS Annual Meeting; San Diego, CA
- 2013: "Pancreatic Tumors: What gastroenterologists need to know." Gastroenterology Fellows Lectures Series, Stanford, CA
- 2012: "Long-term survival after gastric and pancreatic cancer." Comprehensive Cancer Research Training Program (CCRTP), Stanford CA
- 2012: "The Current Therapeutic Approach for Pancreatic Neuroendocrine Tumors: Current Status and Future Directions." ASCO Annual Meeting Education Session, Chicago, IL
- 2012: "Neuroendocrine Tumors: Current Practice & Future Directions." ECOG Spring Meeting 2012, Boston, MA
- 2012: "Neuroendocrine Tumors: ASCO 2012 and current clinical trials." NorCal CarciNET Patient Support Group Meeting, Walnut Creek, CA
- 2011: "Clinical Trials Update." Bay Area NET Patient Education Conference, Stanford, CA
- 2011: "A NET gain: progress towards understanding and treatment neuroendocrine tumors." Stanford Cancer Center Education Seminar Series, Stanford, CA
- 2011: "Standards of Care and Guidelines Update: NETs of the Jejunum, Ileum, Appendix & Cecum." North American Neuroendocrine Tumor Society (NANETS) Annual Symposium, Minneapolis, MN
- 2011: "A NET gain: progress towards understanding and treating neuroendocrine tumors." Massachusetts General Hospital, Boston, MA
- 2011: "A tale of two cancers: Neuroendocrine Tumors and Gastric Cancers." Dana Farber Cancer Institute, Boston, MA
- 2010: "Systemic treatment options in neuroendocrine tumors." Stanford~Caring for Carcinoid Foundation Neuroendocrine Tumor Patient Education Conference, Stanford, CA
- 2010: "Long-term survivorship in gastric cancer." Stanford Oncology-Hematology Annual Research Retreat, Pacific Grove, CA
- 2009: "A phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable neuroendocrine tumors." Stanford Oncology-Hematology Annual Research Retreat, Pacific Grove, CA
- 2009: "Role of EGFR Family Signaling in GI Cancers: Opportunity for Therapeutic Targeting." Stanford Cancer Center Education Seminar Series, Stanford, CA
- 2009: "New approaches for treating stomach cancer." Stanford Cancer Council, Stanford, CA
- 2009: "Pancreatic NETs: What's new?" Caring for Carcinoid Foundation Awareness Weekend, Los Angeles, CA
- 2009 "A NET gain: Progress towards understanding neuroendocrine tumors." Greater Bay Area Cancer Registrars' Meeting, Fremont, CA
- 2009: "A NET gain: progress towards understanding and treatment neuroendocrine tumors." Fox Chase

Cancer Center, Philadelphia, PA

- 2008: “Curiouser and Curiouser.” Department of Medicine Grand Rounds on an ACTH Secreting Pulmonary Neuroendocrine Tumor, Stanford University, Stanford, CA
- 2008: “Gastroenteropancreatic Neuroendocrine Tumors.” Stanford Cancer Center Education Seminar Series, Stanford, CA
- 2007: “A phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results.” Stanford Oncology-Hematology Annual Research Retreat, Pacific Grove, CA

**Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated with Yale:**  
**International/National**

- 2020: Sun, TY Van Hummelen P, Martin B, Xia C, Lee H, Zhao L, Hornbacker K, Ji H, Kunz PL. Comparative genomic analysis of high-grade neuroendocrine neoplasms across diverse organs. European Neuroendocrine Tumor Society (ENETS) Annual Meeting (March 11-13, 2020), Barcelona, Spain. Abstract 2896.
- 2020: Sun, TY Van Hummelen P, Martin B, Xia C, Lee H, Zhao L, Hornbacker K, Ji H, Kunz PL. Comprehensive sequencing of grade 3 neuroendocrine neoplasms. ASCO GI Cancers Symposium (Jan 23-25, 2020), San Francisco, CA. J Clin Oncol. J Clin Oncol 38, 2020 (suppl 4; abstr 624).
- 2020: Duan H, Ninatti G, Girod B, Ferri V, Kunz PL, Fisher GA, Moradi F, Davidzon G, Franc BL, Iagaru A, Aparici CM. Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). ASCO GI Cancers Symposium (Jan 23-25, 2020), San Francisco, CA. J Clin Oncol. J Clin Oncol 38, 2020 (suppl 4; abstr 623).
- 2019: Noll S, Armstrong N, Margulis K, Shankar V, Storey C, Kunz PL; Fishbein L, Zare R, Annes J. Investigating metabolic changes in murine pheochromocytoma models by DESIMSI. Asilomar 2019: Mass Spectrometry Imaging.
- 2019: Duan H, Girod B, Ninatti G, Ferri V, Kunz PL, Fisher GA, Moradi F, Davidzon G, Franc BL, Iagaru A, Aparici CM. Toxicity profile in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumor (NET). Western SNMMI (Nov 1-3, 2019).
- 2019: Duan H, Ninatti G, Girod B, Ferri V, Kunz PL, Fisher GA, Moradi F, Davidzon G, Franc BL, Iagaru A, Aparici CM. Single institution experience with Lutathera® in neuroendocrine tumors (NET). Western SNMMI (Nov 1-3, 2019).
- 2019: Ferone D, Pavel, M, **Kunz P**, de Herder W, Santoro P, Wegener A, Broberg P, Ravasi L, Singh S. LUTATHERA® in first line therapy of G2 and G3 GEP-NETs (the NETTER-2 study).; Poster EP-S-431. EANM (October 12–16, 2019).
- 2019: Delpassand E, Beilei H, Hendifar, A, Hobday T, Krenning E, Kulke M, **Kunz P**, Martin C, Polack B, Ruzniewski P, Santoro P, Strosberg J, Verslype C, Yao J. Impact of Baseline Liver Tumor Burden, Alkaline Phosphatase (ALP) Elevation, and Target Size Lesion on Therapeutic Effect of 177Lu-DOTATATE Treatment: Analysis of Progression Free Survival, and Safety in NETTER-1 Study. NANETS Annual Meeting (Oct 2-5, 2019). Pancreas, 2019 [In Press].
- 2019: Sukerkar, PA, Hornbacker; K, Rosenberg J, **Kunz PL**, Ghanouni P. Correlation Between Somatostatin Treatment and Elevated Hepatic Fat Fraction on MRI in Patients with Neuroendocrine Tumors; Abstract 176. ISMRM Annual Meeting (May 11-16, 2019).

- 2019: Shaheen S, Gardner R, Sundaram V, Hornbacker K, Moradi F, Wu J, Kunz PL. Prevalence of Bone Metastases in Neuroendocrine Neoplasms by <sup>68</sup>Ga Dotatate PET Scan. NANETS Annual Meeting (Oct 2-5, 2019). *Pancreas*, 2019 [In Press].
- 2019: Gupta D, Kappahn K, Qin F, Hornbacker K, Henry S, Wood D, Blayney D, **Kunz PL**. Computing the Cost of Care Per Day for Patients with Metastatic NETs. NANETS Annual Meeting (Oct 2-5, 2019). *Pancreas*, 2019 [In Press].
- 2019: Annes. JP, Horton TM, Holt-Martyn JP, Allegretti PA, Van Vleck A, **Kunz P**, Visser B, Smith, M. NET-Smart Therapy: Developing A Neuroendocrine Tumor-Targeted Chemotherapeutic. NETRF 2019 Research Symposium (May 2-3, 2019).
- 2019: Chan, D, Chan J, Halfdanarson T, **Kunz P**, McGarragh P, Raj N, Reidy-Lagunes D, Thawer A, Whitman J, Wu YL, Singh S. Temozolomide in Grade 3 Neuroendocrine Neoplasms (G3 NENs): A Multicentre Retrospective Review. 16th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease (Mar 6-8, 2019). *Neuroendocrinology*. 2019, 108 (1): abstr H05, page 145.
- 2019: Chan, D, Bergsland EK, Chan J, Gadgil R, Halfdanarson T, Hornbacker K, Kelly V, **Kunz P**, McGarragh PM, Raj NP, Reidy D, Thawer A, Whitman J, Wu L, Singh S. Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review. ASCO GI Cancers Symposium (Jan 17-19, 2019). *J Clin Oncol*. 2019, 37(suppl 4): abstr 321.
- 2018: Strosberg J, Hendifar A, Yao JC, Kulke M, O'Dorisio T, Caplin M, Baum RP, **Kunz P**, Hobday T, Wolin E, Mittra ES, Oberg K, Ruzniewski P, Polack B, He B, Barton D, Santaro P, Krenning E. Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study. 43rd ESMO Congress (ESMO, Oct 19-23, 2018). *Annals of Oncol*. 2018 Oct. 29(8): abstr 1316P.
- 2018: Segelov, E, Bergsland, E, Card, C, Hope, T, **Kunz, P**, Laidley, D, Lawrence, B, Leyden, S, Michael, M, Modahl, L, Myrehaug, S, Padda, S, Pommier, R, Ramirez, R, Soulen, M, Strosberg, J., Thawer, A, Wei, B, Singh, S. The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET). 43rd ESMO Congress (ESMO, Oct 19-23, 2018). *Annals of Oncol*. 2018 Oct. 29(8): Abstr 1322P.
- 2018: Strosberg J, Wolin E, Yao J, Kulke M, Bushnell D, Caplin M, Baum P, **Kunz P**, Hobday T, Hendifar A, Mittra E, Oberg K, Ruzniewski P, Polack B, He B, Santoro P, Krenning E. Impact of baseline liver tumor burden on treatment outcomes with 177Lu-Dotatate in the Netter-1 study. 31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Oct 13-17, 2018. *Eur J of Nuc Med and Molec Imag*. 2018 Oct, 45(1): abstr OP-180, page S60.
- 2018: Pathipati MP, Yohannan,TK, Tian L, Benson JA, Hornbacker K, Berry GJ, Lui N, **Kunz, PL**, Padda S. Examination of Factors Associated With Lymph Node Metastases in Lung Carcinoids. NANETS Annual Meeting (Oct 4-6, 2018). *Pancreas*. 2019: 447.
- 2018: **Kunz PL**, Catalano P, Nimeiri HS, Fisher GA, Longacre TA., Suarez CJ, Yao JC, Kulke MH, Hendifar A, Shanks JC, Shah MH, Zalupski MM, Schmulbach E, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB. A Randomized Study of Temozolomide or Temozolomide and

- Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Trial of the ECOG-ACRIN Cancer Research Group (E2211). NANETS Annual Meeting (Oct 4-6, 2018). Pancreas. 2019: 443.
- 2018: Barnes JI, Lin J, Owens DK, Goldhaber-Fiebert J, **Kunz, PL**. The Cost-Effectiveness of Initial vs Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors in the United States. NANETS Annual Meeting (Oct 4-6, 2018). Pancreas. 2019: 429. *\*oral presentation and merit-based travel award to Dr. Barnes, mentee*
- 2018: Singh S, Bergsland E, Card C, Hope T, **Kunz, P**, Laidley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Segelov E. Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus. J Thoracic Oncol. 2018 Oct, 13(10): abstr P1.12-06.
- 2018: Pumpalova YS, Kozak MM, von Eyben R, Fisher GA, **Kunz PL**, Chang DT, Haraldsdottir S; A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at a single institution. ASCO Annual meeting (June 2018). J Clin Oncol 36, 2018 (suppl; abstr e15573).
- 2018: **Kunz PL**, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, Suarez CJ, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski M, Schmulbach EL, Reidy DL, Strosberg JR, O'Dwyer PJ, Benson AB. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). ASCO Annual Meeting (June 2018). J Clin Oncol 36, 2018 (suppl; abstr 4004). *\*Selected for oral presentation in GI Abstract session; Selected for Best of ASCO 2018.*
- 2018: Mou E, Wittenberg TA, **Kunz PL**, Schapira L. Trust in neuroendocrine tumors: The importance of communication in rare and chronic malignancies. ASCO Cancer Survivorship Symposium (Feb 2018), abstr 75.
- 2018: Pumpalova YS, Kozak MM, von Eyben R, Fisher GA, **Kunz PL**, Chang DT, Haraldsdottir S; A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford. ASCO GI Cancers Symposium (Jan 2018). J Clin Oncol 36, 2018 (suppl 4S; abstr 710).
- 2018: Kardosh A, Tseng D, Sahaf B, Zomet A, Krupa J, Fisher GA, Wang DS, Mackall C, **Kunz PL**. Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies. ASCO GI Cancers Symposium (Jan 2018). J Clin Oncol 36, 2018 (suppl 4S; abstr TPS191).
- 2017: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, **Kunz P**, Hobday T, Hendifa A, Oberg K, Sierra ML, Ruzsniwski P, Krenning E. QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors. NANETS Annual Meeting (Oct 19-21, 2017). Pancreas. 2018 Mar, 47(3): page 355.
- 2017: Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, **Kunz PL**, Anthony LB, Grande E, Oberg K, Welin S, Warner RP, Lombard-Bohas C, Fleming R, Kittur A, Arnold K, Yang QM, Kulke MH. Weight Change Associated With Telotristat Ethyl in the



- Treatment of Carcinoid Syndrome. NANETS Annual Meeting (Oct 19-21, 2017). Pancreas. 2018 Mar, 47(3): page: 357–58.
- 2017: Gutierrez M, Giaccone G, Liu S, Rajan A, Guha U, Halfdanarson T, Curtis K, **Kunz P**, Gabrail N, Hinson J, Orlemans E. Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs). NANETS Annual Meeting (Oct 19-21, 2017). Pancreas. 2018 Mar, 47(3): page 339.
- 2017: Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RP, **Kunz PL**, Grande E, Valle JW, Dillon JS, Lapuerta P, Banks P, Jackson S, Pavel M. NANETS Annual Meeting (Oct 19-21, 2017). Pancreas. 2018 Mar, 47(3): page: 341–42.
- 2017: Pavel M, Benavent M, Perros P, Srirajaskanthan R, Warner RP, Kulke MH, Anthony LB, **Kunz PL**, Hoersch D, Lapuerta P, Fleming R, Gross DJ. Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial. NANETS Annual Meeting (Oct 19-21, 2017). Pancreas. 2018 Mar, 47(3): page: 350.
- 2017: Strosberg J, Wolin EM, Chasen B, Kulke MH, Kulke M, Bushnell D, Caplin M, Baum RP, **Kunz P**, Hobday T, Hendifar A, Oberg K, Sierra ML, Ruzniewski P, Krenning E. Quality of Life Improvements in Patients with progressive Midgut Neuroendocrine Tumors: the NETTER-1 Phase III Trial. Eur J of Nuc Med and Molec Imag. 2017 Oct, 44(2): abstr EP-0804, page S773-774.
- 2017: Strosberg J, Wolin EM, Chasen B, Kulke MH, Bushnell D, Caplin M, Baum RP, **Kunz P**, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Ruzniewski P, Krenning E. Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial. 42nd European-Society-for-Medical-Oncology Congress (ESMO, Sept 8-12, 2017). Annals of Oncol. 2017 Sep, 28(5): abstr 438PD.
- 2017: Horsch D, Kulke MH, Caplin M, Anthony L, Bergsland E, Oberg K, Warner RRP, **Kunz P**, Grande Pulido E, Valle JW, Dillon JS, Lapuerta P, Banks P, Jackson S, Pavel M. Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period. 42nd European-Society-for-Medical-Oncology Congress (ESMO, Sept 8-12, 2017). Annals of Oncol. 2017 Sep, 28(5): abstr 440PD.
- 2017: Fisher GA, Pommier RF, Wolin EM, **Kunz PL**, Liyanage L, Pitman SW, Mirakhur B, Shaheen MF, Vinik A. Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study. ASCO Annual Meeting (Jun 2017). J Clin Oncol. 35, 2017 (suppl; abstr 4088).
- 2017: Weickert, MO, Kaltsas G, Horsch D, LaPuerta P, Pavel M, Valle JW, Caplin ME, Bergsland EB, **Kunz PL**, Anthony LB, Grande E, Oberg KE, Warner RP, Lombard-Bohas C, Welin S, Fleming R, Kittur A, Arnold K, Yang QM, Kulke MH. Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome. ASCO Annual Meeting (Jun 2017). J Clin Oncol. 35, 2017 (suppl; abstr e15692).
- 2017: Strosberg J, Wolin EB, Chasen B, Kulke MH, Bushnell D, Caplin M, Baum R, **Kunz P**, Hobday T, Hendifar A, Öberg K, Lopera Sierra M, Kwekkeboom D, Ruzniewski P, Krenning E. NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors.

- 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease (Mar 8-10, 2017). Neuroendocrinology. 2017, 105(1): abstr N19, page 257.
- 2017: Anthony L, Kulke MH, Hörsch D, Bergsland E, Öberg K, Welin S, Lombard-Bohas C, **Kunz P**, Valle JW, Kassler-Taub K, Fleming R, Pavel M. Impact of Concomitant Medication on Efficacy of Telotristat Ethyl – A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome. 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease (Mar 8-10, 2017). Neuroendocrinology. 2017, 105(1): abstr L2, page 212.
- 2017: Pavel M, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, **Kunz P**, Hörsch D, Lapuerta P, Fleming R, Gross D. Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial. 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease (Mar 8-10, 2017). Neuroendocrinology. 2017, 105(1): abstr K16, page 205.
- 2017: Strosberg JR, Wolin EM, Chasen B, Kulke MH, Bushnell DL, Caplin ME, Baum RB, **Kunz PL**, Hobday TJ, Hendifar AE, Oberg KE, Sierra ML, Kwekkeboom DJ, Ruzniewski PB, Krenning E. Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. GI Cancers Symposium (Jan 2017). J Clin Oncol 35, 2017 (suppl 4S; abstract 348).
- 2017: Pommier RF, Fisher GA, Wolin EM, **Kunz PL**, Liyanage N, Pitman SW, Mirakhur B, ShaheenMF, Vinik A. Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study. ASCO GI Cancers Symposium (Jan 2017). J Clin Oncol 35, 2017 (suppl 4S; abstract 378).
- 2016: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, **Kunz P**, Hobday T, Hendifar A, Oberg K, Sierra ML, Kwekkeboom D, Ruzniewski P, Krenning E. NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results Annual Congress of the European-Association-of-Nuclear-Medicine (EANM, Oct 15-19, 2016). Eur J Nuc Med and Molec Imaging. 2016 Oct, 43 (1): abstr OP394, page S121.
- 2016: Gutierrez M, Giaccone G, Liu S, Rajan A, Guha U, Halfdanarson T, Curtis K, **Kunz P**, Gabrail N, Hinson J, Orlemans E. Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs). ESMO Annual Meeting (October 7-11, 2016). Am J Gastroenterology. 2016 Oct, 111 (1): abstract 423PD).
- 2016: Kulke M, Hörsch D, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Lombard Bohas S, **Kunz P**, Grande E, Valle J, Lapuerta P, Banks P, Jackson S, Jiang W, Biran T, Pavel M. Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome. ESMO Annual Meeting (October 7-11, 2016). Am J Gastroenterology. 2016 Oct, 111 (1): abstract 422PD.
- 2016: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, **Kunz P**, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruzniewski P, Krenning E. NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis. ESMO Annual Meeting (October 7-11, 2016). Am J Gastroenterology. 2016 Oct, 111 (1): abstract 420PD.

- 2016: Fisher G, Wolin E, **Kunz P**, Liyanage N, Mirakhur B, Lowenthal SP, Pommier R, Shaheen M, Vinik A. Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study. ESMO Annual Meeting (October 7-11, 2016). Am J Gastroenterology. 2016 Oct, 111 (1): abstr 440P.
- 2016: Wolin E, Fisher G, **Kunz P**, Liyanage N, Lowenthal SP, Mirakhur B, Pommier R, Shaheen M, Vinik A. Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study. ESMO Annual Meeting (October 7-11, 2016). Am J Gastroenterology. 2016 Oct, 111 (1): abstr 438P, page S468.
- 2016: Fisher GA, Wolin EM, **Kunz PL**, Liyanage N, Mirakhur B, Lowenthal S, Pommier RF, Shaheen M, Vinik A. Efficacy of Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor Patients: Follow-up Analysis of the ELECT Prospective, Randomized, Double-blind and Open-label Phases. NANETS Annual Meeting (Sep 29-Oct 1, 2016). Pancreas. 2017: 433–34.
- 2016: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, **Kunz P**, Hobday T, Hendifar A, Oberg K, Sierra ML, Kwekkeboom D, Ruzsniwski P, Krenning E. NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate: Efficacy, Safety, QoL Results, and Subgroup Analysis. NANETS Annual Meeting (Sep 29-Oct 1, 2016). Pancreas. 2017 Mar, 46(3), 440.
- 2016: Vinik A, Fisher G, **Kunz P**, Liyanage N, Mirakhur B, Lowenthal SP, Pommier R, Shaheen M, Wolin E. Long-Term Safety/Tolerability of Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumors (NETs) Patients With Carcinoid Syndrome (CS): The ELECT Long-Term Open-label Extension. NANETS Annual Meeting (Sep 29-Oct 1, 2016). Pancreas. 2017 Mar, 46(3), 437.
- 2016: Pavel M, Gross D, Benavent M, Caplin M, Perros P, Srirajaskanthan R, Valle J, Warner R, Kulke M, Anthony L, **Kunz P**, Horsch D, Oberg K, Lapuerta P, Jackson S, Banks P, Biran T, Garcia-Carbonero R. Efficacy and Safety Results of Telotristat Ethyl in Patients With Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial, NANETS Annual Meeting (Sep 29-Oct 1, 2016). Pancreas. 2017 Mar, 46(3), 434-5.
- 2016: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, **Kunz P**, Hobday T, Oberg K, Sierra ML, Kwekkeboom D, Ruzsniwski P, Krenning E, Hendifar A. NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate. 18th World Congress of the European-Society-for-Medical-Oncology (ESMO) on Gastrointestinal Cancer (Jun 29-Jul 2, 2016). Annals of Oncol. 2016 Jun, 27 (2): abstr O-009, page 121.
- 2016: Strosberg JR, Wolin EM, Chasen B, Kulke MH, Bushnell DL, Caplin ME, Baum RB, Hobday TJ, Hendifar AE, Oberg KE, Sierra ML, Kwekkeboom DJ, Ruzsniwski PB, Krenning E, **Kunz PL**. NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE. ASCO Annual Meeting (Jun 2016), oral abstract session. J Clin Oncol 34, 2016 (suppl; abstr 4005).

- 2016: Peng S, Saunders L, Bheddah S, Williams S, Aggarwal RR, Shea JE, Lee EY, Huang J, Zemek AJ, Longacre TA, Ball DW, Scaife CL, Nelkin B, Anthony LB, **Kunz PL**, Small EJ, Sylla S. Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC). ASCO Annual Meeting (Jun 2016). J Clin Oncol 34, 2016 (suppl; abstr 11611).
- 2016: Margonis GA, Samaha M, Kim Y, Postlewait LM, **Kunz P**, Maithel S, Tran T, Berger N, Gamblin TC, Mullen MG, Bauer TW, Pawlik TM. A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. 69th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO, Mar 2-5, 2016). J of Gastrointest Surg. 2016 Jun, 20(6):1098-1105.
- 2016: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, **Kunz P**, Hobday T, Hendifar A, Oberg K, Sierra ML, Kwekkeboom D, Ruzsniwski P, Krenning E. NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE: Efficacy and Safety Results. 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease (Mar 9-11, 2016). Neuroendocrinology. 2016, 103(1): Abstr N15, page 95.
- 2016: Pavel M, Horsch D, Anthony L, Ervin C, Kulke M, Bergsland E, Caplin M, Oberg K, Warner R, **Kunz P**, Metz D, Pasieka J, Pavlakis N, DiBenedetti D, Lapuerta P. Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome. 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease (Mar 9-11, 2016). Neuroendocrinology. 2016, 103(1): Abstr M7, page 89.
- 2016: Horsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Lombard-Bohas C, **Kunz P**, Valle J, Fleming D, Lapuerta P, Banks P, Pavel M. Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog Therapy: Analysis of the Ongoing TELESTAR Extension Period. 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease (Mar 9-11, 2016). Neuroendocrinology. 2016, 103(1): Abstr M5, page 88.
- 2016: Williams D, Vinik A, Wolin E, **Kunz P**, Lowenthal SP, Fisher G. Safety and efficacy of lanreotide depot vs. placebo in neuroendocrine tumor patients with a history of carcinoid syndrome and prior octreotide therapy. Oncology Nursing Forum. 2016, 43(2): 133-4.
- 2016: Strosberg JR, Wolin EM, Chasen B, Kulke MH, Bushnell DL, Caplin ME, Baum RP, **Kunz PL**, Hobday TJ, Hendifar AE, Oberg KE, Sierra ML, Kwekkeboom DJ, Ruzsniwski PB, Krenning E. NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. GI Cancers Symposium (Jan 2016), oral presentation. J Clin Oncol 34, 2016 (suppl 4S; abstr 194).  
*\*oral presentation*
- 2015: Zemek AJ, DiMaio MA, Allen J, Vairamuthu H, Balise RR; Longacre TA, **Kunz PL**. Clinical and Immunohistochemical Features of Non-Pancreatic Gastrointestinal Neuroendocrine Neoplasms. NANETS Annual Meeting (Oct 15-17, 2015). Pancreas. 2016 Mar, 45(3): abstr C52.

- 2015: Liu IL, Neal JT, Zemek AJ, **Kunz PL**, Kuo CJ. Patient-Derived Organoids as an In Vitro Model of Neuroendocrine Tumors. NANETS Annual Meeting (Oct 15-17, 2015). Pancreas. 2016 Mar, 45(3): abstr B5.
- 2015: Anthony, L, Hörsch D, Ervin C, Kulke MH; Pavel M, Bergsland E, Caplin M, Öberg K, Warner R, **Kunz PL**, Metz DC, Pasiëka J, Pavlakis N, DiBenedetti D, Haydysch E, Yang QM, Jackson S; Arnold K, Law L, Lapuerta P. Assessing Treatment Benefit of Telotristat Etiprate in Patients with Carcinoid Syndrome: Patient Exit Interviews. NANETS Annual Meeting (Oct 15-17, 2015). Pancreas. 2016 Mar, 45(3): abstr C1, page 470.
- 2015: Fisher GA, Wolin EM, **Kunz PL**, Liyanage N, Gomez-Panzani E, Lowenthal SP, Pommier RF, Shaheen R, Vinik A. Efficacy and Safety of Lanreotide Depot vs Placebo in Patients with Neuroendocrine Tumor and a History of Carcinoid Syndrome and Prior Octreotide Therapy. NANETS Annual Meeting (Oct 15-17, 2015). Pancreas. 2016 Mar, 45(3): abstr C17, page 475.
- 2015: Kulke MH, Niedzwiecki D, Foster NR, Fruth B, **Kunz PL**, Kennecke H, Wolin EM, Venook AP. Randomized Phase II Study of Everolimus (E) versus Everolimus plus Bevacizumab (E+B) in Patients (Pts) with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance). NANETS Annual Meeting (Oct 15-17, 2015). Pancreas. 2016 Mar, 45(3): abstr C23.
- 2015: Kulke MH, Hörsch D, Caplin M, Anthony L, Bergsland E; Öberg E, Welin S, Warner R, Lombard-Bohas C, **Kunz PL**, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P Jackson S, Wheeler D, Zambrowicz B, Sands A, Pavel M. Telotristat Etiprate Shows Benefit in Treating Patients with Carcinoid Syndrome that is Inadequately Controlled by Somatostatin Analog Therapy in the Phase 3 TELESTAR Clinical Trial. NANETS Annual Meeting (Oct 15-17, 2015). Pancreas. 2016 Mar, 45(3): abstr C24, page 478.
- 2015: Libutti SK, Anthony L, Sosa JA, **Kunz PL**, Thomas J, Cruikshank C, Varga A, Chaplin DJ, Burke J, Wolin EM. Phase 2 Study of Fosbretabulin Tromethamine (CA4P) for the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Pancreatic or Gastrointestinal Neuroendocrine Tumors. NANETS Annual Meeting (Oct 15-17, 2015). Pancreas. 2016 Mar, 45(3): abstr C25.
- 2015: Fisher GA, Wolin EM, **Kunz P**, Liyanage N, Gomez-Panzani E, Lowenthal SP, Pommier RF, Shaheen M, Vinik A. Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy. 80th Annual Scientific Meeting of the American-College-of-Gastroenterology (Oct 16-21, 2015). Am J Gastroenterol. 2015 Oct, 110 (1): Abstr 2423, page S1007.
- 2015: Reid T, Fisher G, Carter C, Cho-Phan C, **Kunz P**, Oronsky B, Fanger G, Stirn M, Caroën S, Parker C, Scicinski J. RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET. American-Association-for-Cancer-Research (AACR) Special Conference on Chromatin and Epigenetics in Cancer (Sep 24-27, 2015). Cancer Research. 2016 Jan, 76 (2): Abstr B26.
- 2015: Kulke MH, Hörsch D, Caplin M, Anthony L, Bergsland E, Öberg K, Welin S, Warner R, Lombard-Bohas C, **Kunz P**, Grande E, Valle J, Fleming D, Lapuerta P, Banks P, Jackson S, Wheeler D,

- Zambrowicz B, Sands A, Pavel M. Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial). European Cancer Congress (2015 Sep). European J of Cancer. 2015 Sep, 51 (3): Abstr 37LBA, page S728.
- 2015: Kulke MH, Niedzwiecki D, Foster NR, Fruth B, **Kunz PL**, Kennecke H, Wolin EM, Venook AP. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). ASCO Annual Meeting (June 2015); oral presentation. J Clin Oncol 33, 2015 (suppl; abstr 4005).
- 2015: Reid T, Fisher G, Carter C, Cho-Phan C, **Kunz P**, Oronsky B, Fanger GR, Caroen S, Parker C, Scicinski J. Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer. 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR, Apr 18-22, 2015). Cancer Research. 2015 Aug, 75(15): Abstr CT119.
- 2015: Zemek AJ, DiMaio MA, Kwok SS, Kwok EY, Allen J, Vairamuthu H, Balise RR, **Kunz PL**, Longacre TA. Clinical and Immunohistochemical Features of Non-Pancreatic Gastrointestinal Neuroendocrine Neoplasms. Poster Presentation. 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (Mar 21-27, 2015). Laboratory Investigation. 2015 Feb, 95: Abstr 801, page 201A.
- 2015: Carter C, Reid T, Fisher G, Cho-Phan C, **Kunz P**, Kaiser H, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J. Early Results: “ROCKET” A Phase II Study of RRX-001, a Novel epigenetic Inhibitor, Resensitization to Irinotecan in Colorectal Cancer. 13th International Congress on Targeted Anticancer Therapies (Mar 2-4, 2015). Annals of Oncol, 2015 Mar, 26 (2): Abstr O3.8.
- 2015: DiMaio MA, Zemek AJ, Kwok SS, Kwok EY, Allen J, Vairamuthu H, Balise RR, **Kunz PL**, Longacre TA. Clinical and Immunohistochemical Features of Pancreatic Neuroendocrine Neoplasms. Poster Presentation. 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (Mar 21-27, 2015). Laboratory Investigation. 2015 Feb, 95: Abstr 522, page 133A.
- 2015: Alagappan M, Pollom ER, von Eyben R, **Kunz PL**, Fisher GA, Ford JM, Poultides GA, Visser BC, Norton JA, Kamaya A, Columbo LA, Koong A, Chang DT. Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT. ASCO GI Cancers Symposium (Jan 2015). J Clin Oncol 33, 2015 (suppl 3; abstr 433).
- 2014: Dimaio M, Zemek A, Kwok S, **Kunz PL**, Longacre T. Clinical and Immunohistochemical Features of High Grade Neuroenocrine Neoplasia of the Gastrointestinal Tract, Sa 1141. Gastroenterology, Vol. 146, Issue 5, S-210–S-211. 2014.
- 2014: Liu IH, Ford JM, **Kunz PL**. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. NANETS Annual Meeting (Oct 10-11, 2014); poster presentation.
- 2014: Pollom E, Alagappan M, Cox V, Kamaya A, **Kunz P**, Poultides G, Visser B, Koong A, Chang D. Stereotactic Body Radiotherapy for Pancreatic Adenocarcinoma: Single versus Multi-Fraction. 56th

- Annual Meeting of the American-Society-for-Radiation-Oncology (Sep 14-17, 2014). International J of Rad Oncol Biol Physics. 2014 Sep, 90: Abstr 102, page S50.
- 2014: Denlinger CS, Sym SJ, Bendell JC, Alsina M, Watkins D, Chao Y, Cubillo A, **Kunz PL**, Sun W, Baeksgaard L, Chen L, Horgan K, Frye S, Kudla AJ, McDonagh CF, Czibere AG, Moyo VM, Chibaudel B, Bang Y. Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy. ASCO Annual Meeting (June 2014). J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4148).
- 2014: Nagpal S, Recht C, Imtiaz U, Bertrand S, Thomas B, Ajlan A, Pena J, Gershon M, **Kunz PL**, Li G, Recht, L. Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial. ASCO Annual Meeting (Jun 2014). J Clin Oncol 32:5s, 2014 (suppl; abstr 2096).
- 2014: Cives M, **Kunz P**, Nguyen P, Jump H, Vilay K, Valone T, Strosberg JR. Phase II Clinical Trial of Pasireotide LAR in Patients with Metastatic Neuroendocrine Tumors. 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease (Mar 5-6, 2014). Neuroendocrinology. 2014, 99(3-4): Abstr K3, page 270.
- 2014: Strosberg JR, Jump H, Valone T, Weber J, Khandelwal VH, **Kunz PL**. Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors. ASCO GI Cancers Symposium (Jan 16-18, 2014). J Clin Oncol 32, 2014 (suppl 3; abstr 241).
- 2014: **Kunz PL**, Nandoskar P, Koontz MZ, Ji HP, Ford JM, Kamaya A, Rubin D, Balise RR, Fisher GA. A Phase II Study of Capecitabine, Carboplatin, and Bevacizumab for Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma. ASCO GI Cancers Symposium (Jan 16-18, 2014). J Clin Oncol 32, 2014 (suppl 3; abstr 115).
- 2014: Heestand GM, Murphy J, Moughan J, Regine W, Luo J, Graber M, **Kunz PL**, Fisher GA, Guha C, Lin B, Mowat RB, Gaur R, Buyyounouski MK, Chen Y, Chang D, Koong A. A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704. ASCO GI Cancers Symposium (Jan 16-18, 2014). J Clin Oncol 32, 2014 (suppl 3; abstr 176). *\*oral presentation*.
- 2014: Pollom EL, Alagappan M, Chan C, Shultz D, **Kunz PL**, Koong A, Chang D. Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma. ASCO GI Cancers Symposium (Jan 16-18, 2014). J Clin Oncol 32, 2014 (suppl 3; abstr 317).
- 2012: Lin H, Longacre TA, Khandelwal VH, Balise RR, **Kunz PL**. Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors. J Clin Oncol 30: 2012 (suppl 34; abstr 154).
- 2011: Smyth, EC, Enzinger PC, Li J, Vincitore M, Lacy J, El-Rayes BF, Kunz PL, Ford JM, Robinson E, Kelsen DP, Shah MA. Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. ASCO Annual Meeting (Jun 2011). J Clin Oncol 29: 2011 (suppl; abstr 4056).
- 2011: Gubens M, **Kunz PL**, Fisher GA, Ford JM, D Lichtenstajn, Clarke CA. Long-term survivorship in pancreatic adenocarcinoma. ASCO GI Cancers Symposium (Jan 20-22, 2011). J Clin Oncol 29: 2011 (suppl 4; abstr 175).

- 2011: **Kunz PL**, Gubens M, Fisher GA, Ford JM, D Lichtenstajn, Clarke CA. Long-term survivorship in gastric cancer. ASCO GI Cancers Symposium (Jan 20-22, 2011). J Clin Oncol 29: 2011 (suppl 4; abstr 14).
- 2011: Vossler SR, Bavan B, **Kunz P**, Ford JM, Fisher GA, Whyte R, Koong AC, Chang DT. Multimodality Therapy for Esophageal Cancer: The Benefit of Chemoradiation. International J of Rad Oncol Biol Physics. 2011, 81(2) S309.
- 2010: Bazan JG, Hara W, **Kunz P**, Fisher GA, Ford JM, Welton ML, Koong A, Shelton A, Goodman, KA, Chang DT. Intensity Modulated Radiation Therapy vs. Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. 52nd Annual Meeting of the American-Society-For-Radiation-Oncology (Oct 31-Nov 4, 2010). International J of Rad Oncol Biol Physics. 2010, 78 (3), S300-301.
- 2010: **Kunz PL**, Kuo T, Zahn JM, Kaiser HL, Norton JA, Visser BC, Longacre TA, Ford JM, Balise RR, Fisher GA. A Phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol 28:7s, 2010 (suppl; abstr 4104).
- 2010: He AR, **Kunz PL**, Pishvaian MJ, Colevas AD, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic B. A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer. J Clin Oncol 28, 2010 (suppl; abstr e13090).
- 2010: Christman-Skieller C, Heestand GM, Fisher GA, **Kunz PL**, Ford JM, Columbo LA, Chang DT, Koong A. Treatment of pancreatic cancer in patients age 70 or older. J Clin Oncol 28, 2010 (suppl; abstr e14590).
- 2009: Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, **Kunz P**, Norton JA, Visser BC, Poultsides,GA, Koong AC, Chang DT. Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. 51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO, Nov 1-9, 2009). International J of Rad Oncol Biol Physics. 2012, 82(4): E595-E601.
- 2009: Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, **Kunz P**, Ford JM, Koong AC, Pai RK. Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma. 51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO, Nov 1-9, 2009). Cancer. 2010, 116(22): 5179-5187.
- 2009: Jhaver M, Kindler HL, Wainberg ZA, Ford J, **Kunz P**, Tang L, McCallum SW, Kallender H, and Shah MA on behalf of the MET111643 Investigators and GlaxoSmithKline. Assessment of 2 dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol 27:15s, 2009 (suppl; abstr 4502).
- 2009: Minn A, Fisher G, Ford J, **Kunz P**, Norton J, Koong A, Chang D. Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer. 51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO, Nov 1-9, 2009). Cancer. 2010, 116(16): 3943-3952.
- 2009: Minn A, Fisher G, Ford J, **Kunz P**, Norton J, Koong A, Chang D. Comparison of IMRT and 3D Conformal Radiotherapy for Adjuvant Therapy for Gastric Cancer. 51st Annual Meeting of the



- American-Society-for-Radiation-Oncology (Nov 1-5, 2009). International J of Rad Oncol Biol Physics. 2009, 75(3): S259-S259.
- 2009: Abelson JA, Fisher GA, Ford JM, **Kunz P**, Norton JA, Visser B, Koong AC, Chang DT. Intensity Modulated Radiotherapy for Adenocarcinoma of the Pancreas. 51st Annual Meeting of the American-Society-for-Radiation-Oncology (Nov 1-5, 2009). International J of Rad Oncol Biol Physics. 2009, 75(3): S272-S273.
- 2009: de Bruin MA, **Kunz PL**, Sharma VB, Norton JA, Bastidas JA, Chang DT, Koong AC, Balise RR, Fisher GA, and Ford JM. Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: a retrospective review of the Stanford experience. ASCO Annual Meeting (May 29-Jun 2, 2009). J Clin Oncol 27, 2009 (suppl; abstr e15674).
- 2009: **Kunz PL**, De Bruin MA, Balise RR, Fisher GA, and Ford JM. Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: a retrospective review of the Stanford experience. ASCO Annual Meeting (May 29-Jun 2, 2009). J Clin Oncol 27, 2009 (suppl; abstr e15686).
- 2009: Mittra E , Iagaru A, **Kunz P**, Quon A, Gambhir S. Value of FDG PET/CT for the restaging of colorectal cancer after treatment with Erbitux. J Nuclear Medicine. 2009 May, 50 (2): abstr 1745.
- 2008: Schellenberg D, Kim, J, Columbo L, Lee C, Fisher, GA, **Kunz P**, Maxim PG, Goodman Chang, DT, Koong AC. Phase II trial of single fraction stereotactic body radiotherapy delivered by trilogly linear accelerator for the treatment of locally advanced adenocarcinoma of the pancreas. 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology (Sept 21-25, 2008). International Journal of Rad Oncol Biology Physics. 2008, 72(1): S127-S127.
- 2008: **Kunz P**, Kuo T, Kaiser H, Norton J, Ford J, and Fisher GA. A Phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results. ASCO Annual Meeting (May 30-Jun 3, 2008). J Clin Oncol. 2008 May, 26: abstr 15502.
- 2004: **Kunz P**, Reiss T, and Koin D. Escherichia coli 0157:H7 infection in nursing homes: review of literature and report of recent outbreak. Poster presentation at the ACP California Meeting (October 2004).
- 2004: Vij R, Triadafilopoulos G, Owens DK, **Kunz, P**, Sanders GD. Cost-effectiveness analysis of photodynamic therapy for treatment of high-grade dysplasia in Barrett's esophagus. 25th Annual Meeting of the Society-for-Medical-Decision-Making (Oct 19-22, 2003). Gastrointestinal Endoscopy, 2004 Nov, 60(5): 739-756.
- 2003: Vij R, Triadafilopoulos G, Owens DK, **Kunz, P**, Sanders GD. Cost-effectiveness analysis of photodynamic therapy for treatment of high-grade dysplasia in Barrett's esophagus. Digestive Disease Week 2003 Meeting/104th Annual Meeting of the American-Gastroenterological-Association (May 17-22, 2003). Gastrointestinal Endoscopy, 2003 April, 57(5): AB79.

**Invited Speaking Engagements, Presentations, Symposia & Workshops Affiliated with Yale:**

- 2021: Department of Pediatrics, Status of Women in Medicine (SWIM) monthly meeting, invited guest
- 2021: Gastroenterology Grand Rounds, Neuroendocrine Tumors: A Primer for Gastroenterologists”

- 2021: Yale Cancer Center Grand Rounds, “The Yale Center for Gastrointestinal Cancers: Challenges and Opportunities”
- 2021: Yale Clinical Trials Office Lunch & Learn, “Neuroendocrine Tumors”
- 2021: Therapeutic Radiology Grand Rounds, “Does Radiation Work for Neuroendocrine Tumors?”
- 2021: Developmental Therapeutics Research Program Seminar, “Neuroendocrine Tumors: Clinical Advances and Translational Opportunities”
- 2021: Molecular Imaging Clinical and Translational Research Laboratory Presentation, “Integrating Theranostics into the Broader NET Diagnostic and Treatment Algorithm”
- 2020: “Neuroendocrine Tumors: Where Endocrinology and Medical Oncology Intersect.” Endocrinology Grand Rounds, Yale.
- 2020: “Update on Gastrointestinal Cancers.” Yale ASCO Review.
- 2020: Lunch Career Talk, Medical Research Scholars Program (MSRP), Yale

### **Professional Service**

#### **Peer Review Groups/Grant Study Sections:**

- 2019-2020 NET Research Foundation Grant Reviewer
- 2014-present North American Neuroendocrine Tumor Society (NANETS) Grant Reviewer

#### **Advisory Boards:**

- 2020 NETTER-2 Steering Committee Member, Novartis (Advanced Accelerator Applications)

#### **Journal Service:**

##### Editorial Boards:

- 2021-present Consultant Editor of Meeting Proceedings, Journal of Clinical Oncology
- 2020-present Associate Editor, Journal of Neuroendocrinology
- 2020-present Peer Perspective Board Member, Healio’s Women in Oncology
- 2018-2021 Specialty Editor, Neuroendocrine Tumors Section, Cancer.Net
- 2013-present Associate Editor, Pancreas

##### Reviewer:

Ad hoc manuscript reviewer: ASCO Educational Book, Cancer Endoscopy, Clinical Cancer Research, Gastrointestinal Cancer Research, Journal of Clinical Oncology, Journal of Clinical Oncology Precision Oncology, Journal of the Endocrine Society, Journal of Hematology and Oncology, Journal of Gastrointestinal Cancer, Journal of the National Comprehensive Cancer Network (JNCCN), Lancet, Pancreas, The Oncologist, Translational Gastroenterology and Hepatology, Women’s Health

### **Professional Service for Professional Organizations:**

#### ***American Association for Cancer Research (AACR)***

2007- present Member

***National Cancer Institute (NCI)***

- 2021-2025 Standing Member, FDA Oncologic Drugs Advisory Committee (ODAC)
- 2020-present Chair, National Cancer Institute Neuroendocrine Tumor Task Force
- 2019-2020 Co-Chair, National Cancer Institute Neuroendocrine Tumor Task Force, Clinical Trial Planning Meeting
- 2017-2020 Vice Chair, National Cancer Institute Neuroendocrine Tumor Task Force
- 2010-2011 Junior Member, National Cancer Institute Neuroendocrine Tumor Task Force

***American College of Physicians (ACP)***

- 2001-2015 Member

***North American Neuroendocrine Tumor Society (NANETS)***

- 2019-2020 Chair, Membership and Diversity Committee, NANETS
- 2018-present Treasurer, NANETS
- 2015-present Board of Directors, NANETS
- 2014-2015 Member, NANETS Research Committee
- 2012-2013 Member, NANETS Education Committee
- 2011-2012 Co-Chair, Guidelines Committee (NANETS)
- 2010- present Member

***American Society of Clinical Oncology (ASCO)***

- 2021-present Member, ASCO Gastrointestinal Cancer Guideline Advisory Group (GAG)
- 2019-2022 Member, ASCO Annual Meeting Scientific Program Committee, Professional Development and Education Advances Track
- 2019-2020 Track Leader, ‘Professional Development and Education Advances, American Society of Clinical Oncology (ASCO) Annual Meeting Scientific Committee
- 2013-2014 Track Leader, ‘Gastrointestinal Cancers (Non-Colorectal) Track’, American Society of Clinical Oncology (ASCO) Annual Meeting Cancer Education Committee
- 2011-2014 ASCO Annual Meeting Cancer Education Committee, GI Cancers (Non-Colorectal) Track
- 2006-present Member

***International Society for GI Oncology (ISGIO)***

- 2019 International Society for GI Oncology, NET Session Co-Chair

***Association of Northern California Oncologists (ANCO)***

- 2015-2016 Board of Directors, Association of Northern California Oncologists
- 2009-2020 Member

***Eastern Cooperative Oncology Group (ECOG)***

- 2014-2017 Leader, ECOG Neuroendocrine Tumor Working Group
- 2010-present Member

***Healing Kitchens***

2018-present Advisor

***National Comprehensive Cancer Network***

- 2021 Panelist for “Creating a More Equitable Care Delivery System” as part of the NCCN Policy Summit: Defining the “New Normal” 2021 and the State of Cancer Care in America Following 2020.
- 2009-2019 Panel on Neuroendocrine Tumors, National Comprehensive Cancer Network (NCCN, Stanford representative)

***Society for Abdominal Radiology – Disease Focused Panel (Neuroendocrine Tumors)***

2020-present Member

**University Service**

***Leadership Positions***

- 2021-present Member, Internal Advisory Board, DeLuca Center for Innovation in Hematology Research
- 2021-present Vice Chief, Diversity, Equity and Inclusion, Section of Medical Oncology
- 2021-present Co-Leader, Neuroendocrine Tumor Program, Yale
- 2020-present Director, Center for Gastrointestinal Cancers, Yale
- 2020-present Section Chief, GI Medical Oncology, Yale
- 2018-2020 Director, Neuroendocrine Tumor Fellowship, Stanford
- 2018-2020 Leader, Endocrine Oncology Research Group, Stanford
- 2015-2020 Director, Stanford Neuroendocrine Tumor Program
- 2015-2018 Leader, GI Clinical Research Group, Stanford
- 2015-2017 Associate Director, Oncology Fellowship Program, Stanford
- 2013-2017 Director, Inpatient Oncology Service (Med 10), Stanford
- 2012-2015 Co-Leader, GI Clinical Research Group, Stanford

***Medical School Committees and Service***

- 2021-2022 Chair, Search Committee for GI Medical Oncologist
- 2021-present Co-Chair, Search Committee for Division Chief of Surgical Oncology
- 2021-present Lactation Working Group, Yale School of Medicine
- 2020-present Core Faculty, Department of Medicine, Hematology-Oncology Fellowship Program
- 2020-present Liaison to the Division of Oncology, Status of Women in Medicine (SWIM), Yale
- 2020-present Member, Liver Cancer Summit Executive Committee, Yale
- 2020-present Member, Liver Cancer Program Steering Committee, Yale
- 2020-present Member, Pancreas Cancer Collaborative (PaCC) Executive Committee, Yale
- 2020-2021 Chair, Search Committee for GI Medical Oncologist
- 2019-2020 Member, Department of Medicine, Diversity and Inclusion Committee, Stanford
- 2016-2020 Interviewer, Endocrine Fellowship Program, Stanford
- 2016-2018 Member, Department of Radiology / Nuclear Medicine Faculty Search Committee, Stanford

2014-2018 Member, Quarterly Heme/Onc Fellow Research Review Committee, Stanford  
 2013-2020 Member, Stanford Cancer Institute  
 2013-2014 Core Faculty, Internal Medicine Residency Program, Stanford  
 2013-2014 Core Interviewer, Internal Medicine Residency Program, Stanford  
 2013 Member, CME Strategic Planning Committee, Stanford  
 2012-2015 Member, GI Clinical Research Group, Stanford  
 2010-2020 Interviewer, Stanford Hematology / Oncology Fellowship Program, Stanford  
 2010-2013 Associate Member, Stanford Cancer Center, Stanford  
 2009-2010 Mentor, Intensive Course in Clinical Research sponsored by Stanford Packard Center for Translational Research in Medicine, Stanford  
 2009-2020 Interviewer, Stanford Internal Medicine Residency Program, Stanford  
 2007-2020 Member, Stanford Developmental Therapeutics Committee, Stanford

***Clinical and Hospital Service***

2021-present Clinical Trial Matching Pilot in GI Oncology  
 2021-present Protocol Activation Committee, Clinical Trials Office, Yale Cancer Center  
 2021-present Clinical Trial Advisory Committee, Clinical Trials Office, Yale Cancer Center  
 2021-present Member, Solid Tumor - Team Structure Workgroup  
 2020-present Member, GI Tumor Board, Yale  
 2020-present Attending Physician, GI Oncology Clinic, Yale  
 2020-present Attending Physician, Inpatient Oncology Service, Yale  
 2018-2020 Member, NET Tumor Board, Stanford  
 2018-2020 Attending Physician, Endocrine Oncology Clinic, Stanford  
 2014-2017 Med 8, 9, 10 Services Committee Member and “Structure” Team Leader, Stanford  
 2014-2015 Member, Cancer Center Tumor Board Redesign Committee, Stanford  
 2014-2015 Member, Cancer Hospital Planning Committee, Stanford  
 2010-2011 Member, Stanford Cancer Center Committee on Patient Scheduling, Stanford  
 2009-2020 Attending Physician, Inpatient Oncology Service, Stanford  
 2009-2018 Attending Physician, Gastrointestinal Oncology Clinic, Stanford  
 2009-2020 Member, Gastrointestinal Oncology Tumor Board. Stanford

**Public Service**

2020-present Scientific Advisory Board Member, Sara Schottenstein Foundation (Gastric Cancer)  
 2020-present Advisor, Pre-Med Club, King’s Academy, Sunnyvale, CA  
 2019-2020 Advisor, Pre-Med Club, Menlo-Atherton High School, Atherton, CA  
 2018-present 1994 Giving Team, Dartmouth College  
 2015-present Alumni Interviewer, Dartmouth College  
 2015-2020 Member, Board of Directors, Menlo-Atherton Little League, Menlo Park, CA  
 2010-2017 Coach, American Youth Soccer Organization (AYSO), Menlo Park, CA

## Bibliography

### Peer-reviewed original research

1. Coughlin EM, Christensen E, **Kunz PL**, Krishnamoorthy KS, Walker V, Dennis NR, Chalmers RA, Elpeleg ON, Whelan D, Pollitt RJ, Ramesh V, Mandell R, and Shih VE. Molecular analysis and prenatal diagnosis of human fumarase deficiency. Molecular Genetics & Metabolism. 1998; 63(4):254-62. PMID: 9635293.
2. Filiano JJ, Bellimer SG, and **Kunz PL**. Tandem mass spectrometry and newborn screening: pilot data and review. Pediatric Neurology. 2002; 26(3):201-204. PMID: 11955927.
3. Vij R, Triadafilopoulos G, Owens DK, **Kunz P**, and Sanders GD. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointestinal Endoscopy. 2004; 60(5):739-56. PMID: 15557950.
4. Chang ST, Zahn JM, Horecka J, **Kunz PL**, Ford JM, Fisher GA, Le QT, Chang DT, Ji H and Koong AC. Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. Journal of Translational Medicine. 2009; 11(7):105. PMID: 20003342.
5. La TH, Minn AY, Su Z, Fisher GA, Ford JM, **Kunz P**, Goodman KA, Koong AC, and Chang DT. Multi-modality Treatment with Intensity Modulated Radiation Therapy for Esophageal Cancer. Dis Esophagus. 2010 May;23(4):300-8. Epub 2009 Aug 28. PMID: 19732129.
6. Chennupati SK, Kamaya A, Fisher GA, Ford JM, **Kunz P**, Itakura H, Welton ML, Shelton A, Van Dam J, Koong AC, and Chang DT. Pathologic response after chemoradiation for T3 rectal cancer. Colorectal Dis. 2010 Jul;12(7 Online):e24-30. Epub 2009 Jul 15. PMID: 19614668.
7. Schellenberg DS, Quon A, Minn AY, Graves EE, **Kunz P**, Ford JM, Fisher GA, Goodman KA, Norton JA, Koong AC, and Chang DT. (18)Fluorodeoxyglucose-PET is prognostic of progression free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Aug 1; 77(5):1420-5. Epub 2010 Jan 7. PMID: 20056345.
8. Minn AY, Hsu A, La TH, **Kunz PL**, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, and Chang DT. Comparison of IMRT and 3D Conformal Radiotherapy for Adjuvant Therapy for Gastric Cancer. Cancer. 2010 Aug 15; 116(16):3943-52. PMID: 20564136.
9. Chang DT, Chapman CH, Norton JA, Visser B; Fisher GA, **Kunz P**, Ford JM, Koong AC, and Pai RK. Expression of p16INK4A but not hypoxia markers or PARP is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer. 2010 Nov 15;116(22):5179-87. PMID: 20665497.
10. Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford, JM, Fisher GA, **Kunz PL**, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, and Koong AC. Single Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):181-8. Epub 2011 May 5. PMID: 21549517.
11. Norton J, Harris E, Chen Y, Visser B, Poultsides G, **Kunz P**, Fisher G, and Jensen R. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011; 146(6):724-732. PMID: 21690450.

12. Bazan JG, Hara W, Hsu A, **Kunz P**, Ford J, Fisher GA, Welton ML, Shelton A, Koong AC, Goodman KA, Chang DT. Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. Cancer. 2011; 117(15):3342-51. PMID: 21287530.
13. Zissen MH, **Kunz P**, Fisher, GA, and Quon A. 18F-5-fluorouracil Dynamic PET/CT Reveals Decreased Tracer Uptake After Bevacizumab in Colorectal Metastasis. 2011; 32(5):343-7. PMID: 21412178.
14. Abelson JA, Murphy JD, Minn AY, Chung MP, Fisher GA, Ford JM, **Kunz P**, Norton JA, Visser BC, Poultides GA, Koong AC, Chang DT. Intensity Modulated Radiotherapy for Pancreatic Adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e595-601. PMID: 22197234.
15. Chang, DT, Pai, RK, Rybicki LA, DiMaio MA, Limaye M, Jayachandran P, Koong AC, **Kunz P**, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012; 25(8):1128-1139. PMID: 22481281.
16. **Kunz PL**, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, and Pai RT. HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis with Proposed Systematic Algorithmic Approach to HER2 Assessment. Applied Immunohistochemistry and Molecular Morphology. 2012; 20(1):13-24. PMID: 21617552.
17. Poultides GA, Huang LC, Chen Y, Pai RK, Jeffrey RB, ParkWG, Chen AM, **Kunz PL**, Fisher HGA, Norton JA. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Ann Surg Oncol. 2012 Jul;19(7):2295-303. Epub 2012 Mar 7. PMID: 22396008.
18. **Kunz PL**, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: A California population-based study. Journal of Clinical Oncology. 2012 Oct 1;30(28):3507-15. Epub 2012 Sep 4. PMID: 22949151.
19. **Kunz PL**, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Investigational New Drugs. 2012 Dec;30(6):2364-70. PMID: 22331549.
20. Shah MA, Wainberg MA, Catenacci DVT, Hochster HS, Ford J, **Kunz P**, Lee F, Kallender H, Cecchi F, Rabe DC, Keer H, Martin A, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in Patients with Metastatic Gastric Cancer. PLOS ONE. 2013;8(3):e54014. Epub 2013 Mar 14. PMID: 23516391.
21. Patel MI, Rhoads KF, Ma Y, Ford JM, Visser BC, **Kunz PL**, Fisher GA, Chang DT, Koong A, Norton JA, Poultides GA. Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement? Ann Surg Oncol. 2013 May;20(5):1631-8. PMID: 23149854.

22. Qadan M, Ma Y, Visser BC, **Kunz PL**, Fisher GA, Norton JA, Poultsides GA. Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors. J Am Coll Surg. 2014 Feb;218(2):188-95. PMID: 24321190.
23. Worhunsky DJ, Krampitz GW, Poullos PD, Visser BC, **Kunz PL**, Fisher GA, Norton JA, Poultsides GA. Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB (Oxford). 2014 Apr;16(4):304-11. PMID: 23991643.
24. Shultz DB, Chan C, Shaffer JL, **Kunz PL**, Chang DT. Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. Pancreas. 2014 Jul;43(5):777-83. PMID: 24632549. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. 2014 Nov 15;90(4):918-25, Epub 2014 Oct 18. PMID: 25585785.
25. Cives M, **Kunz P**, Morse B, Schell MJ, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg J. Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015 Feb;22(1):1-9. Epub 2014 Nov 6. PMID: 25376618.
26. Nagpal S, Recht CK, Bertrand S, Thomas RP, Ajlan A, Pena J, Gershon M, Coffey G, **Kunz PL**, Li G, Recht LD. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high-grade glioma. J Neurooncol. 2015 Jun;123(2):277-82. Epub 2015 May 3. PMID: 25935109.
27. Scicinski J, Fisher G, Carter C, Cho-Phan C, **Kunz P**, Ning S, Knox, S, Oronsky B, Caroan S, Parker C, Fanger G, Reid T. The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. Redox biology. 2015 Aug;5:422. PMID: 28162292.
28. Margonis GA., Samaha M, Kim Y, Postlewait LM, **Kunz P**, Maithel S, Thuy Tran T, Berger N, Gambelin TC, Mullen MG, Bauer TW, Pawlik TM. A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. J Gastrointest Surg. 2016 Jun;20(6):1098-105. PMID: 27008594.
29. Cloyd JM, Kopecky KE, Norton JA, **Kunz PL**, Fisher GA, Visser BC, Dua MM, Park WG, Poultsides GA. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. Surgery. 2016 Sep;160(3):708-13. PMID: 27216830.
30. **Kunz PL**, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero M, Ko AH, Korn M, Hwang J, Bergsland EK. Oxaliplatin-fluoropyrimidine chemotherapy plus bevacizumab in advanced neuroendocrine tumors: An analysis of two phase II trials. Pancreas. 2016 Nov;45(10):1394-1400. PMID: 27171514.
31. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, **Kunz PL**, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT and Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. JCO. 2017 Jan;35(1):14-23. Epub 2016 Oct 28. PMID: 27918724.
32. Strosberg, J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, **Kunz PL**, Kulke MH, Jacene H, Bushnell, D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni



- E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruzniewski P, Kwekkeboom E, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of  $^{177}\text{Lu}$ -Dotatate for Midgut Neuroendocrine Tumors. *NEJM*. 2017 Jan 12;376(2):125-135. PMID: 28076709.
33. Anthony L, Ervin C, Lapuerta P, Kulke MH, **Kunz P**, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. *Clin Ther*. 2017 Nov;39(11):2158-2168. Epub 2017 Oct 23. PMID: 29074312.
  34. Pavel ME, Gross, DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony L, **Kunz PL**, Horsch D, Weickert MO, LaPuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy in the TELECAST Phase 3 Trial. *Endocrine Related Cancer*. Epub Jan 12, 2018. PMID: 29330194.
  35. Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, **Kunz PL**, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. *Clin Ther*. 2018 Apr 30. pii: S0149-2918(18)30148-6. PMID: 29724499.
  36. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, **Kunz P**, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruzniewski P, Krenning E; NETTER-1 Study Group. Health-Related Quality of Life in Patients with Progressive Midgut Neuroendocrine Tumors Treated With  $^{177}\text{Lu}$ -Dotatate in the Phase III NETTER-1 Trial. *J Clin Oncol*. 2018 Sep 1;36(25):2578-2584. PMID: 29878866.
  37. Kardosh A, Lichtensztajn DY, Gubens MA, **Kunz PL**, Fisher GA, Clarke CA. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. *Pancreas*. 2018 Sep;47(8):958-966. PMID: 30074526.
  38. Erdrich J, Schaberg KB, Khodadoust MS, Zhou L, Shelton AA, Visser BC, Ford JM, Alizadeh AA, Quake SR, **Kunz PL**, Beausang JF. Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. *Cold Spring Harb Mol Case Stud*. 2018 Oct 1;4(5). PMID: 30087100.
  39. Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P, Mendoza-Villanueva D, De La Vega FM, **Kunz PL**, Liao JC, Leppert JT, Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ. Organoid Modeling of the Tumor Immune Microenvironment. *Cell*. 2018 Dec 13;175(7):1972-1988.e16. PMID: 30550791.
  40. Pumpalova YS, Kozak MM, von Eyben R, Fisher GA, **Kunz PL**, Chang DT, Haraldsdottir S. Comparison of Definitive Chemoradiation with 5-fluorouracil versus capecitabine in Anal Cancer. *J Gastrointest Oncol*. 2019 Aug;10(4):605-615. PMID: 31392040.
  41. Toriihara A, Baratto L, Nobashi T, Park A, Hatami N, Davidzon G, **Kunz PL**, Iagaru A. Prognostic value of volumetric parameters calculated from  $^{68}\text{Ga}$ -DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. *European Journal of Nuclear Medicine and Molecular*

- Imaging. Eur J Nuc Med Molec Imaging, Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2244-2251. PMID: 31350603.
42. Assi HA, Mukherjee S, **Kunz PL**, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Surgery vs. surveillance for well-differentiated non-functional pancreatic neuroendocrine tumors: An eleven-year analysis of the National Cancer Database. Oncologist. 2020 Feb;25(2):e276-e283. PMID: 32043766.
  43. Strosberg J, **Kunz PL**, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruzsniwski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajakanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E; NETTER-1 study group. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020 Mar 2, [Epub ahead of print]. PMID:32123969.
  44. Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, **Kunz PL**, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. J Gastrointest Cancer. 2020 Mar 7. [Epub ahead of print]. PMID32146619.
  45. Riess JW, Jahchan NS, Das M, Zach Koontz M, **Kunz PL**, Wakelee HA, Schatzberg A, Sage J, Neal JW. A phase IIa study repositioning desipramine in small cell lung cancer and other high grade neuroendocrine tumors. Cancer Treat Res Commun. 2020 Apr 20;23:100174. doi: 10.1016/j.ctarc.2020.100174. Epub ahead of print. PMID: 32413603; PMCID: PMC7572629.
  46. Horton TM, Sundaram V, Lee CH, Hornbacker K, Van Vleck A, Benjamin KN, Zemek A, Longacre TA, **Kunz PL**, Annes JP. PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker. Sci Rep. 2020 Jul 2;10(1):10943. doi: 10.1038/s41598-020-68071-6. PMID: 32616904; PMCID: PMC7331689.
  47. Barnes JJ, Lin JK, Gupta D, Owens DK, Goldhaber-Fiebert JD, **Kunz PL**. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. J Natl Compr Canc Netw. 2020 Sep;18(9):1200-1209. doi: 10.6004/jnccn.2020.7563. PMID: 32886901.
  48. Pathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, **Kunz PL**, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer. 2021 Apr;154:186-194. doi: 10.1016/j.lungcan.2021.01.017. Epub 2021 Jan 23. PMID: 33551175; PMCID: PMC8026717.
  49. Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, **Kunz PL**, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. J Gastrointest Cancer. 2021 Mar;52(1):212-221. doi: 10.1007/s12029-020-00375-2. PMID: 32146619; PMCID: PMC7714089.
  50. Pathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, **Kunz PL**, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer. 2021 Apr;154:186-194. doi: 10.1016/j.lungcan.2021.01.017. Epub 2021 Jan 23. PMID: 33551175; PMCID: PMC8026717.

51. Cheng E, Blackburn HN, Ng K, Spiegelman D, Irwin ML, Ma X, Gross CP, Tabung FK, Giovannucci EL, **Kunz PL**, Llor X, Billingsley K, Meyerhardt JA, Ahuja N, Fuchs CS. Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. *JAMA Netw Open*. 2021 Jun 1;4(6):e2112539. doi: 10.1001/jamanetworkopen.2021.12539. PMID: 34132794; PMCID: PMC8209612.
52. Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, **Kunz PL**, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. *Oncologist*. 2021 Aug 3. doi: 10.1002/onco.13923. Epub ahead of print. PMID: 34342086.

### Book chapters

53. Minsky BD, Ford JM, **Kunz PL**, and Norton JA. Cancer of the Stomach. In: Leibel's Textbook of Radiation Oncology, Third Edition edited by Steven Leibel, MD, Theodore L. Phillips, MD, Richard T. Hoppe, MD, FACR, and Mack Roach, III, MD; 2010.
54. Heestand G, **Kunz PL**, and Fisher GA. The Evolution of Modern Systemic Agents for Colorectal Cancer. In: Radiation Medicine: Lower Gastrointestinal Malignancies. Editors: Albert Koong, MD PhD and Edgar Ben-Josef, MD; 2010.
55. Norton JA and **Kunz PL**. Neuroendocrine tumors of the lungs and gastrointestinal tract (carcinoid tumors). In: CANCER: Principles & Practice of Oncology, 10<sup>th</sup> edition. Editors: Vincent T. DeVita, Jr., MD, Theodore S. Lawrence, MD, PhD, and Steven A. Rosenberg, MD, PhD; 2014.
56. Norton JA and **Kunz PL**. Multiple Endocrine Neoplasias. In: CANCER: Principles & Practice of Oncology, 10<sup>th</sup> edition. Editors: Vincent T. DeVita, Jr., MD, Theodore S. Lawrence, MD, PhD, and Steven A. Rosenberg, MD, PhD; 2014.

### Peer-reviewed review articles

57. **Kunz, P** and Fisher G. Preclinical and early clinical data on TRAIL in colon cancer. Advances in Colon Cancer. 8 (2), 2007.
58. **Kunz PL**. A Renaissance in Therapeutic Options for Pancreatic Neuroendocrine Tumors. In: Govindan R, ed. 2012 ASCO Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2012;271-274. PMID: 24451747.
59. **Kunz PL** and Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical and Experimental Gastroenterology; 2010 Jun 10; 3:79-86. PMID: 21694850.
60. Narayanan S, **Kunz PL**. Role of Somatostatin Analogs in the Treatment of Neuroendocrine Tumors? J Natl Compr Canc Netw. 2015 Jan;13(1):109-17. PMID: 25583773.
61. Narayanan S, **Kunz PL**. Beyond biologics: Is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors? International Journal of Endocrine Oncology. 2015, 2(1):13–20. PMID: 25583773.
62. Phan AT, **Kunz PL**, Reidy-Lagunes DL. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Clin Adv Hematol Oncol. 2015 May;13(5 Suppl 5):1-18. PMID: 26430956.
63. Narayanan S and **Kunz PL**. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016 Feb;30(1):163-77. PMID: 26614375.

64. Liu IH, Ford JM, and **Kunz PL**. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Cancer Treat Rev. 2016 Mar;44:1-9. Epub 2015 Dec 24. PMID: 26924193.
65. Liu, IH and **Kunz PL**. Biologics in gastrointestinal and pancreatic neuroendocrine tumors. J Gastrointest Onc. 2017 Jun;8(3):457-465. PMID: 28736633.
66. Waseem N, Aparici CM, **Kunz PL**. State of the Art: Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms. J Nuclear Medicine. 2019 [Epub ahead of print]. PMID: 30850504.
67. Shaheen S, Moradi F, Gamino G, **Kunz PL**. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Curr Treat Options Oncol. 2020 Mar 14;21(4):25. PMID: 32172368.

### Invited Editorials and Commentaries

68. **Kunz, PL**. Carcinoid and Neuroendocrine Tumors: Building on Success. J Clin Oncol. 2015 Jun 1;33(16):1855-63. Epub 2015 Apr 27. PMID: 25918282.
69. **Kunz PL**. Understanding Neuroendocrine Tumors—A NET Gain. JAMA Oncol, Invited Commentary. 2017 Oct 1;3(10):1343-1344. PMID: 28448658.
70. **Kunz PL**. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. PMID: 33152282.

### Practice Guidelines, Standards and Consensus Statements

1. Clark OJ, Ajani JA, Benson AB 3<sup>rd</sup>, Berlin JD, Blaskowsky LS, Byrd D, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, **Kunz P**, Kvolts, L, Olson JA Jr, Ratliff TW, Salem R, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg, JR, Vauthey, JN, Yao JC; NCCN Neuroendocrine Tumor Panel Members. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors. J Natl Compr Canc Netw. 2009; 7(7):712-47. PMID: 19635226.
2. Kulke MH, Benson AB 3<sup>rd</sup>, Bergsland E, Berlin JD, Blaskowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, **Kunz PL**, Kuvshinoff BW 2<sup>nd</sup>, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 June, 10(6):724-64. PMID: 22679117.
3. **Kunz PL**, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas. 2013 May;42(4):557-577. PMID: 23591432.
4. Kulke MH, Shah MH, Benson AB 3<sup>rd</sup>, Bergsland E, Berlin JD, Blaskowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, **Kunz PL**, Kuvshinoff BW 2<sup>nd</sup>, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015 Jan;13(1):78-108. PMID: 25583772.
5. Strosberg JR, Halfdanarson TR, Bellizi AM, Chan JA, Dillon JS, Heaney AP, **Kunz PL**, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC,

- Tang L, Zacks JS, Yao JC, Bergsland EB. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. *Pancreas*. 2017 Jul;46(6):707–714. PMID: 28609356.
6. Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, **Kunz PL**, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. *J Nucl Med*. 2018 Jan;59(1):66-74. PMID: 29025982.
  7. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, **Kunz PL**, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. *J Natl Compr Canc Netw*. 2018 Jun;16(6):693-702. PMID: 29891520.
  8. Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, **Kunz PL**, Mailman J, Menda Y, Metz DC, Mitra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy. *J Nucl Med*. 2020 Feb;61(2):222-227. PMID: 32015164.
  9. Singh S, Bergsland EK, Card CM, Hope TA, **Kunz PL**, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. *J Thorac Oncol*. 2020 Oct;15(10):1577-1598. doi: 10.1016/j.jtho.2020.06.021. Epub 2020 Jul 11. PMID: 32663527.
  10. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, **Kunz PL**, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. *Pancreas*. 2020 Jul;49(6):723-728. doi: 10.1097/MPA.0000000000001561. PMID: 32433264; PMCID: PMC7253037.
  11. Singh S, Bergsland EK, Card CM, Hope TA, **Kunz PL**, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. *J Thorac Oncol*. 2020 Oct;15(10):1577-1598. doi: 10.1016/j.jtho.2020.06.021. Epub 2020 Jul 11. PMID: 32663527.
  12. Ho K, Flaseriu M, Kaiser U, Salvatori R, Brue T, Lopes MB, **Kunz P**, Molitch M, Camper SA, Gadelha M, Syro LV, Laws E, Reincke M, Nishioka H, Grossman A, Barkan A, Casanueva F, Wass J, Mamelak A, Katznelson L, van der Lely AJ, Radovick S, Bidlingmaier M, Boguszewski M, Bollerslev J, Hoffman AR, Oyesiku N, Raverot G, Ben-Shlomo A, Fowkes R, Shimon I, Fukuoka H, Pereira AM, Greenman Y, Heaney AP, Gurnell M, Johannsson G, Osamura RY, Buchfelder M,

- Zatelli MC, Korbonits M, Chanson P, Biermasz N, Clemmons DR, Karavitaki N, Bronstein MD, Trainer P, Melmed S. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? *J Endocr Soc*. 2021 Feb 9;5(3):bvaa205. doi: 10.1210/jendso/bvaa205. PMID: 33604494; PMCID: PMC7874572.
13. Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, **Kunz PL**, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. *Pancreas*. 2021 Apr 1;50(4):469-493. doi: 10.1097/MPA.0000000000001792. PMID: 33939658.
  14. Singh S, Hope T, **Kunz PL**. Executive Summary of the National Cancer Institute Gastrointestinal Steering Committee Neuroendocrine Tumor Clinical Trials Planning Meeting: Treatment in the Era of Peptide Receptor Radionuclide Therapy March 8-9, 2021. <https://www.cancer.gov/about-nci/organization/ccct/steering-committees/nctn/gastrointestinal/gisc-net-prrt-ctpm-execsum.pdf>

### Perspectives and Opinions

15. Mou E, Schapira L, **Kunz P**. The Power of Trust. *JAMA Oncol*. 2018 Sep 1;4(9):1173-1174. PMID: 29710067.

### Case Reports, Technical Notes, and Letters

16. Reiss T, **Kunz P**, Koin D, and Keeffe EB. Escherichia coli 0157:H7 Infection in Nursing Homes: Review of the literature and report of a recent outbreak. *J Am Geriatr Soc*. 2006; 54:680–684. PMID: 16686882.
17. Wanta SM, Basina M, Chang SD, Chang DT, Ford JM, Kingham K, Merritt RE, **Kunz PL**. A Rare Case of an Aldosterone Secreting Metastatic Adrenocortical Carcinoma and Papillary Thyroid Carcinoma in a 31-year-old Male. *Rare Tumors*. 2011; 3(4):e45. PMID: 22355500.
18. Ambrosy AP, **Kunz PL**, Fisher GA, Witteles RM. Capecitabine-Induced Chest Pain Relieved by Diltiazem. *American Journal of Cardiology*. 2012 Dec 1;110(11):1623-6. PMID: 22939579.
19. Koontz MZ, Visser BM, **Kunz PL**. Neoadjuvant Imatinib for Borderline Resectable Gastrointestinal Stromal Tumors. *J Natl Compr Canc Netw*. 2012; 10:1477-1482. PMID: 23221786.
20. Tello TL, Zeidan YH, Bush K, Schwartz E, **Kunz P**, Chang DT. Penile metastases originating from a pancreatic primary tumor: a case report. *J Radiat Oncol*. 2012; 2(1):107-112.
21. Subramaniam S, Zell, JA, **Kunz PL**. Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis. *J Natl Compr Canc Netw*. 2013;11(1):5-9. PMID: 23307976.
22. Paudel N, **Kunz PL**, Poultsides GA, Koong AC, Chang DT. False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. *Pract Radiat Oncol*. 2014 Nov-Dec;4(6):368-71. Epub 2013 Dec 16. PMID: 25407856.
23. Gerson JN, Witteles RM, Chang DT, Beygui RE, Iagaru IH, **Kunz PL**. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report. *Pancreas*. 2017 Nov/Dec;46(10):1381-1385. PMID: 29040196.

24. Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, **Kunz PL**. Rapid Progression After <sup>177</sup>Lu-DOTATATE in Patients With Neuroendocrine Tumors. *Pancreas*. 2021 Jul 1;50(6):890-894. doi: 10.1097/MPA.0000000000001841. PMID: 34398071.

### **Scholarship in Press**

25. **Kunz PL**, Franchetti Y, Catalano, PJ, Stuart K, Sheiman RB, Miksad, RA, Chapman W, Sigurdson ER, Kauh JS, Staley CA, Haller DG, Benson AB. Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multicenter Trial: A trial of the ECOG-ACRIN Cancer Research Group (E4298), *Oncologist*, *In Press 2021*.

## **CAREER DEVELOPMENT**

### **Other Post-Graduate Education**

- |      |   |
|------|---|
| 2007 | AACR / ASCO Clinical Trials Workshop<br>Selected to develop protocol: A Phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.   |
| 2008 | Intensive Course in Clinical Research sponsored by Stanford / Packard Center for Translational Research in Medicine<br>Selected to develop protocol: A case-control study of gastroenteropancreatic neuroendocrine tumors to evaluate environmental and genetic risk factors. |
| 2019 | Clayman Gender Research Institute Faculty Fellowship<br>Selected to develop study examining gender of PIs on Phase III clinical trials in GI Oncology.  |

### **Leadership Courses**

- |      |  |
|------|--|
| 2013 | Stanford Faculty Fellows Leadership Program (Director: H. Valentine)                 |
| 2015 | Stanford Faculty Leadership Development Program (Director: J. Hopkins)               |
| 2018 | Stanford Leadership Program in Mindfulness (Directors: R. Merrill and B. Harrington) |

## **TEACHING**

### **A. Leadership roles**

1. Course Director, “Neuroendocrine Tumors in 2017: New Diagnostics and Therapies.” Stanford CME; Stanford, CA, November 18, 2017.
2. Invited Chair, GI Oncology Panel, Northern California Multidisciplinary Management of Cancers (March 17, 2019).

### **B. Formal Course Teaching**

1. “Clinical and Translational Aspects of Neuroendocrine Tumors,” Lecture in Cancer Bio 242, Stanford University School of Medicine: Scientific and Translational Basis for Clinical Cancer Therapy; May 26, 2015.
2. “Colorectal cancer screening and prevention,” Lecture in CHPR 260, Stanford University School of Medicine: Prevention Across Medical Disciplines; May 3, 2016.

**C. Recurring Lectures**

1. Preceptor, Practice of Medicine, Stanford University School of Medicine (2007-9)
2. Monthly Stanford Inpatient Oncology Service Resident Lecture: “Colon Cancer Screening and Treatment,” (2007-9)
3. Annual Internal Medicine Housestaff Lecture (Stanford and Palo Alto VA campuses) GI Cancer Topic (2010-2020)
4. Annual Stanford Physician Assistant Teaching Program Lecture GI Cancer Topic (2011-2020)
5. Annual Stanford Palliative Care Fellows Lecture, “GI Tumors, Therapies and Disease Course,” (2015-2020)
6. Annual Stanford GI Fellows Lecture, “Pancreatic Tumors,” (2015-2020).
7. Annual Stanford Endocrine Fellows Lecture, “Neuroendocrine Tumors,” (2015-2020).

**D. Recurring Conferences**

1. Stanford Oncology Division Friday Journal Club
2. Stanford Oncology Division Annual Research Retreats
3. Stanford Oncology Division Cancer Education Series
4. Northern California Multidisciplinary Management of Cancers (2007 - 2020)  
\*Invited Chair, GI Oncology Panel (2019)
5. Yale ASCO Review Annual CME Course, GI Cancer Update (2020-present)



**E. Mentoring of Students, Post-Doctoral Fellows, and Junior Faculty at Stanford University**

<b>Clinical Trainees</b>	<b>Position/Year mentored</b>	<b>Current position</b>
M. Zach Koontz, MD	Oncology Fellow, Stanford 2010-2011	Attending Physician Hematologist/Oncologist, Pacific Cancer Care, Monterey, CA
Soma Subramaniam, MD, MS	Oncology Fellow, Stanford Continuity Fellow, 2011-2014	Attending Hematologist/Oncologist, Swedish Medical Center, Seattle WA
Eric Mou, MD	Internal Medicine Resident and Oncology Fellow, Stanford Inpatient and Outpatient, 2014- 2017	Hematology/Oncology Fellow, Stanford  As of July 2020: Assistant Professor of Medicine/Hematology University of Iowa
Tian Zhang, MD PhD	Oncology Fellow, Stanford Continuity Fellow, 7-12/2014	Hematology/Oncology Fellow, Stanford
Tyler Johnson, MD	Oncology Fellow, Stanford Continuity Fellow, 2015/2016	Clinical Assistant Professor of Medicine/Oncology, Stanford
Anoop Manjunath	Stanford University Undergrad Clinic Shadow Experience 2016-2019	Stanford Medical Student, Knight-Hennessey Scholar
Jeff Zweig, MD	Oncology Fellow, Stanford Continuity Fellow, 7-12/2016	Attending Physician Hematologist/Oncologist, Kaiser Permanente, CA
Sisi Haraldsdottir, MD	Assistant Professor Medicine/Oncology, Stanford 2015-2019	Assistant Professor Medicine/Oncology Dana Farber Cancer Institute

<b>Research Trainees</b>	<b>Position/Year mentored</b>	<b>Current position</b>
Lisa Jacobs, MD	Stanford University Undergraduate Research Intern 2008-2010	Pediatrics Chief Resident, UCLA
Nate Wilcox-Fogel, MD	Clinical Research Assistant 2010-2012	Orthopedic Surgery Resident, Stanford
Hillary Lin, MD	Stanford Medical Student Stanford Med Scholar 2011-2018	CEO, GutSavvy.com
Iris Liu, BA	Dartmouth College Undergraduate	Medical Student, UCSF

	Research Intern 2013-2020	
Minyoung Kang, MD	Visiting International Scholar July 2015-June 2016	Attending Hematologist/Oncologist Inje University Haeundae Paik Hospital Busan, South Korea
Sukhmani Padda, MD	Assistant Professor Medicine (Oncology) 2015-present	Assistant Professor Medicine (Oncology)
Adel Kardosh, MD PhD	GI Onc Research Fellow 2016-2018	Assistant Professor, GI Medical Oncology, OHSU
Shagufta Shaheen, MD	Neuroendocrine Tumor Fellow, 2018-2019	Clinical Assistant Professor of Medicine/Oncology, Stanford
Naj Waseem, MD	Internal Medicine Resident, Stanford 2017-2019	Hematology/Oncology Fellow, Johns Hopkins
Thomas Sun, MD	Internal Medicine Resident, Stanford 2017-present	Heme/Onc Fellow, Stanford
Divya Gupta, MD	Internal Medicine Resident, Stanford 2017-present	Heme/Onc Fellow, Stanford
Hussein Assi, MD	Heme/Onc Fellow, Univ Oklahoma September 2019	Assistant Professor of Medicine/Hematology Boston University
Gerardo Gamino	BYU Undergraduate Summer Intern Summer 2019	BYU Undergraduate
Sophie Cotton	Bachelor of Biomedical Science/Bachelor of Law Southern Cross University Australia Jan-March 2020	Applying for Masters Programs

## DIGITAL SCHOLARSHIP AND OUTREACH

### Webinars

1. **Kunz P.** NETs 101, Stanford CME Course; launched December 2018.  
<https://stanford.cloud-cme.com/course/courseoverview?P=0&EID=20960>

2. **Kunz P**, Halperin D, Bergsland E, Howe J. NET Patient Care in the Era of COVID, NANETS Webinar; launched Mar 2020.  
<https://vimeo.com/411532327>
3. **Kunz P**. “Improving health-related quality of life within the framework of the multidisciplinary NET team (TouchIME CME);” available online June 2020.  
<https://www.touchoncology.com/gastroenteropancreatic-neuroendocrine-tumours/>
4. **Kunz P**. Updates in the Management of Neuroendocrine Tumors (Onc Live News Network/Post ASCO Perspectives), June 2020.
5. **Kunz P**. The ABCs of Neuroendocrine Cancer: 2020 Update. The Carcinoid Cancer Foundation, launched, July 2020.  
<https://www.youtube.com/user/CarcinoidNETs>
6. **Kunz P**. American Association of Endocrine Surgeons Facebook Live NET Awareness Month Webinar, November 19, 2021.
7. **Kunz P**. Carcinoid Cancer Foundation Luncheon with the Experts via Facebook Live, January 14, 2021.  
[https://www.facebook.com/watch/live/?v=1734297806754856&ref=watch\\_permalink](https://www.facebook.com/watch/live/?v=1734297806754856&ref=watch_permalink)

#### Podcast Guest

8. **Outspoken Oncology**, a podcast hosted by Dr. Chadi Nabhan. “Gender Discrimination and Harassment in Academic Medicine,” September 1, 2020.  
<https://podcasts.apple.com/us/podcast/gender-discrimination-harassment-in-academic-medicine/id1456378352?i=1000489732904>
9. **Project Purple**, a podcast hosted by Dino Verrelli. “Fighting for a cure,” October 9, 2020.  
<https://podcasts.apple.com/us/podcast/episode-133-fighting-for-a-cure-with-dr-pamela-kunz-md/id1355013636?i=1000494155477>
10. **Oncology Overdrive**, a podcast hosted by Dr. Shikha Jain. “Addressing Gender Discrimination and Harassment in Medicine,” October 12, 2020.  
<https://www.healio.com/news/hematology-oncology/resources/oncology-overdrive/episode-20>
11. **Yale Cancer Answers**, a podcast hosted by Dr. Anees Chagpar. Colorectal Cancer and Neuroendocrine Tumors. November 22, 2020.  
<https://www.yalecancercenter.org/patient/answers/programs/>
12. **Beyond the Journal**, a podcast hosted by Drs. Charu Aggaral & Jack West. “Professional Advancement as a Woman, & Changing Cultures that Enable Sexual Harassment.” June 1, 2021.  
<https://podcasts.apple.com/us/podcast/dr-pamela-kunz-on-professional-advancement-as-woman/id1537647937?i=1000525588966>
13. **Oncology Journal Club**, a podcast hosted by Dr. Eva Segelov. “ASCO 2021 GI Special with Marc Peeters and Pam Kunz.” June 17, 2021.  
<https://podcasts.apple.com/us/podcast/ojc-episode-40-asco-2021-gi-special-marc-peeters-pam/id1507244171?i=1000527532546&l=cs>

#### Other Digital Impact

1. **Room Rater** score 9/10, June 15, 2021  
<https://twitter.com/ratemyskyperoom/status/1404877983786078215>

#### TV INTERVIEWS AND OTHER MEDIA

##### TV Interviews

1. WSFB CBS. Young Colorectal Cancer. September 6, 2020.
2. WNTH. Young Colorectal Cancer. October 28, 2020.  
<https://www.wtnh.com/health-2/yale-doc-says-lowering-recommended-age-for-colon-screening-is-critical-following-rise-in-colorectal-cancer-in-younger-patients/>

### Other Media

1. **The Cancer Letter**, “Pamela Kunz: In any other industry, if someone had behavior like that, they would be fired,” October 2, 2020. \*Top 10 article in 2020  
[https://cancerletter.com/conversation-with-the-cancer-letter/20201002\\_3/](https://cancerletter.com/conversation-with-the-cancer-letter/20201002_3/)
2. ASCO Daily News, “With the Problem of Gender Diversity in Oncology Well Established, Education Session Focuses on Solutions.” April 1, 2021.  
<https://dailynews.ascopubs.org/doi/10.5555/ADN.21.200503/full/>
3. **ASCO Post Living a Full Life Series**, “Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce,” August 25, 2021.  
[https://ascopost.com/issues/august-25-2021/neuroendocrine-tumor-specialist-pamela-kunz-looks-to-promote-equity-in-the-workforce/?utm\\_source=TAP%2DeTOC%2D082521&utm\\_medium=email&utm\\_term=b75e54cb134c0c974ade101263c5df86](https://ascopost.com/issues/august-25-2021/neuroendocrine-tumor-specialist-pamela-kunz-looks-to-promote-equity-in-the-workforce/?utm_source=TAP%2DeTOC%2D082521&utm_medium=email&utm_term=b75e54cb134c0c974ade101263c5df86)